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ABSTRACT OF THE DISSERTATION 
Pathophysiology and Treatment of Murine Globoid Cell Leukodystrophy 
by 
Yedda Li 
Doctor of Philosophy in Biology and Biomedical Sciences 
Genetics and Genomics 
Washington University in St. Louis, 2020 
Professor Mark S. Sands, Chair 
Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a rapidly progressing, 
invariably fatal pediatric disorder first described in 1916. Krabbe disease is caused by a deficiency 
in the lysosomal enzyme, galactosylceramidase (GALC), and is characterized clinically by failure 
to thrive, limb stiffness, seizures, developmental regression, and death by 2-4 years of age. 
Galactosylceramidase degrades the cytotoxic glycolipid, galactosylsphingosine (psychosine). In 
the absence of GALC activity, psychosine accumulates primarily in oligodendrocytes and 
Schwann cells, resulting in profound demyelination. In 1972, psychosine was hypothesized to be 
responsible for the clinical signs associated with Krabbe disease. However, the ‘Psychosine 
Hypothesis’ has never been tested, due to the inability to dissociate GALC deficiency from 
psychosine accumulation. This is due, in part, to a limited understanding of psychosine 
biosynthesis. Two studies published in 1960 and 1973 provided complementary evidence 
suggesting that psychosine is synthesized via an anabolic pathway. However, neither the cDNA 
nor the enzyme catalyzing that reaction has been identified. In the first part of this dissertation, we 
overturn those studies and show that psychosine is generated catabolically through the deacylation 
of galactosylceramide by acid ceramidase (ACDase). This reaction effectively dissociates GALC 
xvii 
deficiency from psychosine accumulation, allowing us to test and confirm the ‘Psychosine 
Hypothesis.’ These data also identify ACDase as a potential target for substrate reduction therapy 
(SRT). We show that pharmacological inhibition of ACDase activity significantly prolongs the 
lifespan of the Twitcher (Twi) mouse, a GALC-deficient model that faithfully mimics the 
biochemical, histological, and clinicobehavioral features of Krabbe disease. These data clarify our 
understanding of psychosine synthesis, confirm the long-held ‘Psychosine Hypothesis,’ and 
provide the impetus to discover safe and effective inhibitors of ACDase to treat Krabbe disease. 
Although Krabbe disease is a monogenic disorder, it is remarkably refractory to treatment, 
and single modality therapies are minimally effective. However, combining CNS-directed, adeno-
associated virus (AAV) 2/5-mediated gene therapy, hematopoietic stem cell transplantation, and 
SRT greatly increases efficacy in the Twi mouse. In the second part of this dissertation, we 
incorporated a newer generation vector, AAV2/9, into this combination therapy regimen. This 
single change significantly increased the lifespan of Twi mice. Importantly, it also dramatically 
improved, and in some cases, normalized, the clinicobehavioral deficits that remained uncorrected 
in mice treated with the AAV2/5-combination therapy. Unfortunately, nearly all of the AAV2/9-
combination-treated Twi mice and all combination-treated wild type control mice died from 
hepatocellular carcinoma (HCC). Integration site analysis confirmed AAV sequence incorporation 
into the mouse genome. These data demonstrate the value of targeting multiple pathogenic 
mechanisms for complex metabolic diseases, but highlight the potential risks associated with these 
approaches. 
Taken together, the data presented in this dissertation greatly advance the field of Krabbe 
research by increasing our fundamental understanding of Krabbe pathogenesis, and by making 
significant progress in the treatment of this fatal disease. Modification of the combination therapy 
xviii 
regimen to include a safe, ACDase-inhibiting SRT to target psychosine synthesis, as well as a liver 






































1.1 Krabbe Disease (Globoid Cell Leukodystrophy) 
Krabbe disease (globoid cell leukodystrophy, GLD) is a rapidly progressing, invariably 
fatal, pediatric lysosomal storage disorder. Krabbe was first described in 1916 by the German 
pediatrician, Dr. Knud Krabbe, as a “diffuse sclerosis of the brain” (Krabbe, 1916). It is caused by 
a deficiency in the lysosomal enzyme galactosylceramidase (GALC), which is responsible for 
cleaving the terminal galactose from galactosylated lipids such as galactosylceramide and 
galactosylsphingosine. Galactosylsphingosine, more commonly known as psychosine, is a toxic 
metabolite that accumulates quickly in oligodendrocytes and Schwann cells in the absence of 
GALC activity. Death of these myelinating cells results in a demyelinating phenotype that is 
characterized primarily by stiffness, spastic paralysis, hyperreactivity, and blindness. 
 
1.2 Clinical Presentation 
There is a very wide range of presentation and clinical progression for Krabbe disease. 
Early infantile Krabbe disease, the most severe form of GLD, is also the most common form. 
Children with the early infantile form present during the first year of life most noticeably with 
difficulty feeding and hyperirritability. Feeding difficulties include difficulty latching on, 
uncoordinated sucking and swallowing, coughing and gagging, and fatigue. Infants also exhibit 
signs of gastrointestinal dysmotility, including gastroparesis, vomiting, and constipation (Escolar 
et al., 2006). Disease progression occurs rapidly, with children developing hypertonicity, 
hyperreactivity, opisthoclonus, and mental/motor regression. Patients are also unusually prone to 
pneumonia, ear infections, and urinary tract infections, most likely due to an unidentified immune 
defect (Anderson et al., 2014). Optic nerve atrophy is often observed, resulting in vision loss. In 
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the final stages of disease, patients are decerebrate, blind, and often also deaf (Hagberg et al., 1963). 
Signs of autonomic dysfunction are observed, including hyperthermia and hypothermia, vascular 
leakage, and widening blood pressure variations (Escolar et al., 2016). Most patients with early 
infantile Krabbe die before age two. 
The later-onset forms of Krabbe disease present with a milder clinical picture and have a 
more protracted disease course. Children with the late infantile form present at 6 months to 3 years, 
whereas the children with the juvenile form present from 3-8 years of age. Unlike early infantile 
Krabbe patients, who present most commonly with hyperirritability and gastrointestinal problems, 
patients with later-onset Krabbe disease often present with loss of vision and ataxia (Lyon et al., 
1991). 
The least common form of Krabbe disease is adult-onset Krabbe. These patients are often 
misdiagnosed with multiple sclerosis (MS), because symptoms at presentation are 
indistinguishable from those of MS patients. Unlike patients with childhood-onset Krabbe, patients 
with adult-onset Krabbe can be stable for long periods of time without treatment, although some 
patients experience a steady decline in function, ultimately resulting in death (Debs et al., 2013).  
 
1.3 Histopathology 
Long before the enzyme deficiency responsible for causing Krabbe disease was ever 
identified, pathological characterization of this disease revealed the existence of multinucleated, 
distended “globoid cells” in the central nervous system (CNS) (Collier and Greenfield, 1924). 
Lipid content characterization of brains from Krabbe patients later identified the buildup of 
galactosylceramide in globoid cells (Blackwood and Cumings, 1954). Interestingly, this elevation 
in galactosylceramide was not observed in whole brain. Because galactosylceramide is a major 
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component of myelin, it was hypothesized that the eponymous “globoid cells” were fused 
macrophages working in futility to phagocytose and degrade the myelin debris that accumulated 
in a chronically and profoundly demyelinated state (Austin and Lehfeldt, 1965). More recently, it 
has been shown that microglia, but not macrophages, transform into globoid cells when exposed 
to psychosine in vitro (Ijichi et al., 2013), suggesting that these eponymous cells may actually be 
of microglial origin. 
 
1.4 Clinical Management 
Currently, there is no cure for Krabbe disease. The standard of care is hematopoietic stem 
cell transplantation (HSCT), either in the form of bone marrow transplantation or umbilical cord 
blood transplantation. HSCT can delay symptom onset and disease progression, but is not a cure 
(Wright et al., 2017).  Furthermore, HSCT is effective only if administered prior to symptom onset, 
which necessitates the detection of disease through genetic testing. Because New York and 
Missouri are the only states that provide newborn screening for Krabbe, most children treated for 
Krabbe disease are siblings of another affected sibling, and many children are no longer able to 
receive treatment by the time they are diagnosed. In fact, there is evidence suggesting that some 
infants as young as one month can no longer benefit from HSCT therapy (Orsini et al., 2016). 
Since HSCT carries significant risk and is associated with significant mortality and morbidity, we 






1.5 Newborn Screening 
Newborn screening for Krabbe disease was initiated in the United States in 2006, and 
continues to be very controversial. This is due in part to the unclear genotype-phenotype 
associations in Krabbe disease, especially for patients with later-onset Krabbe disease (Debs et al., 
2013). Only five of fourteen children who were categorized as “high risk” for having Krabbe 
disease have developed clinical signs and symptoms consistent with the disease (Orsini et al., 
2016). Furthermore, there is significant overlap in GALC activity between patients who have 
Krabbe disease, carriers, and normal individuals. Because the current treatment for Krabbe disease, 
HSCT, is associated with significant risks, it is unclear how high-risk patients should be treated, 
as it is unclear whether or not they will go on to develop symptomatic Krabbe. 
Currently, newborn screening assays for GALC activity in dried blood spots are done by 
mass spectrometry or by fluorometry. Although this gives a direct readout for the genetic 
determinant of Krabbe disease, GALC activity alone is not a very specific predictor for Krabbe 
disease. A significant fraction of patients with very low GALC activity have yet to develop any 
signs or symptoms of Krabbe disease. Quantification of the buildup of psychosine, the toxic 
metabolite that accumulates in Krabbe disease, is a secondary measure by which the specificity of 
newborn Krabbe screening can be increased. In fact, psychosine measurements are already being 
used to quantify treatment effect and disease progression in Krabbe disease (Escolar et al., 2017). 
Recent studies that quantified psychosine in dried blood spots showed psychosine elevation in 
patients affected by Krabbe disease compared to carriers and normal control patients (Turgeon et 
al., 2015). It remains to be seen whether psychosine accumulation can be used as a secondary, or 
even primary, screening tool for Krabbe disease. 
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1.6 Animal models 
There are several naturally-occurring animal models of Krabbe disease: the mouse 
(Kobayashi et al., 1980; Duchen et al., 1980), the terrier dog (Victoria et al., 1996), the Australian 
Kelpie dog (Fletcher et al., 2010), the nonhuman primate (Baskin et al., 1998), the cat  (Sigurdson 
et al., 2002), and the sheep (Pitchard et al., 1980). 
1.6.1 The Twitcher mouse model 
First observed in 1976 at the Jackson Laboratory in Bar Harbor, Maine, the Twitcher (Twi) 
mouse is the oldest, most studied model of Krabbe disease (Kobayashi et al., 1980; Duchen et al., 
1980). The Twi mouse has a premature termination codon (W339X) in the GALC gene, which 
results in nonsense-mediated decay of the GALC mRNA (Lee et al., 2006). As such, Twi mice 
have complete absence of GALC expression, which parallels the most common 30 kB deletion 
resulting in complete absence of GALC activity in human Krabbe patients (Luzi et al., 1995). All 
patients with this mutation develop infantile Krabbe disease. In addition to the genetics, Twi mice 
also mirror the biochemistry, histology, and clinicopathological features of infantile Krabbe 
disease. Twitcher mice have a very profound phenotype consisting of severe tremor, failure to 
thrive, ataxia, hind limb atrophy, and kyphosis. Mice first develop symptoms at postnatal day 15, 
and disease progression occurs rapidly, with death occurring at ~40 days (Taniike and Suzuki, 
1994). Histologically, the eponymous globoid cells are observed in Twi brains, accompanied by 
massive microgliosis and astrocytosis (Reddy et al., 2011). Because of its relative availability and 





1.6.2 The West Highland terrier dog model 
Another important model of Krabbe disease is canine GLD in West Highland white terriers. 
This disease manifests as profound CNS demyelination, psychosine accumulation, and presence 
of globoid cells in the white matter of affected animals (Wenger et al., 1999). More recently, 
another naturally-occurring canine model of Krabbe disease was discovered in Australian Kelpies. 
Krabbe disease in Australian Kelpies manifests as a demyelinating disease with ataxia, tremors, 
paralysis, and a severely shortened lifespan. Histologically, the disease is characterized by 
microglial and astrocytic activation, as well as axonal spheroid formation (Fletcher et al., 2010). 
Canine Krabbe disease is a large animal model of Krabbe disease that is integral for 
translating experimental therapies into the clinic. The canine West Highland white terrier model 
of Krabbe disease has been used to determine the effectiveness of gene therapy in correcting the 
Krabbe phenotype (Bradbury et al., 2018). These data are particularly important, because the dog 
is closer to the human than the mouse in brain size, and will likely more accurately predict 
treatment efficacy for the human disease. 
1.6.3 The nonhuman primate model 
The only nonhuman primate model of Krabbe disease is the rhesus macaque (Baskin et al., 
1998). Like the mouse and canine models of Krabbe, this is a naturally-occurring model with a 
2bp deletion in exon 4 of the GALC gene. This results in frameshift and a premature termination 
codon in the mRNA (Luzi et al., 1997). Macaques homozygous for this mutation present with 
severe tremors, ataxia, hypermetria, respiratory difficulties, nerve conduction abnormalities, and 
significantly shortened lifespan (Borda et al., 2008). Nonhuman primate Krabbe is characterized 
histologically by presence of globoid cells and profound microgliosis (Borda et al., 2008). 
Although primate models are expensive to maintain, these models are critical for drug 
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development and translation of experimental therapies into the clinic. A case study of 
mesenchymal stem cell transplantation in a one-month old rhesus macaque with early infantile 
Krabbe disease transiently improved coordination, ambulation, cognition, and gross motor skills 
(Isakova et al., 2017). Although the benefits of this treatment were temporary, the findings in this 
study suggest that rhesus macaques have a Krabbe phenotype most closely representative of human 
Krabbe. Because non-human primates are also more similar in anatomy and physiology than other 
mammalian species, they are an ideal model to evaluate experimental therapies before they can be 
moved to human study. In another case study, the feasibility of primate gene therapy 
administration has been confirmed (Meneghini et al., 2016). The results from this study will likely 




1.7.1 Pathogenic mechanisms in Krabbe disease 
Although Krabbe is a monogenic disease, it is also a very complex disease. Multiple 
pathogenic mechanisms interact to contribute to disease progression (Figure 1.1). The inherent 
deficiency in GALC activity is the very tip of the iceberg. Galactosylceramidase deficiency 
directly results in psychosine accumulation. Psychosine accumulation in turn, results in death of 
Schwann cells and oligodendrocytes, which leads to demyelination. Additionally, there have been 
some data suggesting a dysmyelinating phenotype in addition to the demyelinating one (Potter et 
al., 2013). Demyelination activates microglia and astrocytes, and recruits macrophages to the CNS 
to clean up myelin debris. The result is profound neuroinflammation, oxidative stress, and free 
radical generation. Unlike the glial activation observed in ordinary CNS maintenance, the 
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neuroinflammation in Krabbe is chronic and unattenuable, because the microglia are unable to 
clean up the myelin debris due to the inherent GALC deficiency. Deficiency of GALC activity, 
psychosine accumulation, demyelination/dysmyelination, oxidative stress, and neuroinflammation 
all coexist and interact in the Krabbe nervous system to wreak havoc and create the momentum 
for disease progression. The coexistence and interactions between these pathogenic mechanisms 
become critically important when considering the potential therapies for this complex disease. 
1.7.2 Galactosylceramidase deficiency 
In 1970, two separate groups identified the enzyme defect associated with Krabbe disease 
as that of the lysosomal enzyme galactosylceramidase (Malone, 1970; Suzuki and Suzuki, 1970). 
The cDNA for the human GALC gene was identified and cloned in 1993 (Chen et al., 1993) after 
the mutation responsible for Krabbe disease was mapped to human chromosome 14 (Zoglotora et 
al., 1990). 
1.7.3 Psychosine 
After GALC was identified as the disease-causing gene in Krabbe disease, another substrate 
for GALC was identified – psychosine (Miyatake and Suzuki, 1972). Unlike galactosylceramide, 
which was only elevated in globoid cells and not elevated in whole brain, psychosine was found 
to be massively elevated in the brains of Krabbe patients (Svennerholm et al., 1980). Studies of 
the properties of psychosine revealed it to be severely toxic to all cell types, with especially rapid 
effects on oligodendrocytes (Cho et al., 1997), Schwann cells (Tanaka and Webster, 1993), and 
glial cells (Jatana et al., 2002). In addition, psychosine promotes DNA fragmentation, increases 
proapoptotic factors, inhibits oligodendrocyte maturation, and promotes peripheral axonal 
demyelination (Yamada and Suzuki, 1999; Jatana et al., 2002; Haq et al., 2003; Khan et al., 2005; 
Contreras et al., 2008; Giri et al., 2008). In light of its toxicity, Miyatake and Suzuki proposed the 
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‘Psychosine Hypothesis’ in 1972, which states that psychosine, not GALC deficiency, is the 
primary cause of the Krabbe phenotype (Miyatake and Suzuki, 1972). Although this hypothesis 
has been generally accepted within the field for many years, it has never been formally tested, due 
to the inability to dissociate psychosine accumulation from GALC deficiency. 
Figuratively speaking, psychosine has been a thorn in the side for the Krabbe research 
community. Other than the unproven ‘Psychosine Hypothesis,’ there are many other unanswered 
questions regarding this toxic compound. Until very recently, even the mechanism by which 
psychosine exerts its toxic effect was unknown. Psychosine is a relatively small, amphipathic 
molecule. It has been unclear how psychosine could have so many wide-ranging effects without 
interacting with a great number of different proteins. Although both receptor-mediated and 
membrane-disrupting mechanisms for toxicity have been proposed (Im et al., 2001); White et al., 
2009), there is now compelling evidence to suggest that membrane disruption is the main 
mechanism by which psychosine effects its toxicity. In 2013, it was shown that both naturally-
occurring psychosine and its enantiomer, ent-psychosine, were equally toxic. Because protein 
interactions in the natural world are specific for chirality, these results suggested that psychosine 
mediates its toxic effects not through protein interactions, but by disrupting the lipid rafts in 
cellular membranes (Hawkins-Salsbury et al., 2013). 
How psychosine is produced is also unclear. There are two potential pathways of 
psychosine synthesis in vivo: 1. the anabolic dehydration of galactose and sphingosine and 2. the 
catabolic deacylation of galactosylceramide. It was shown in 1960 that psychosine could be 
produced in vitro by the anabolic dehydration of galactose and sphingosine (Cleland and Kennedy, 
1960). In 1973, an independent group indirectly confirmed these results by concluding that the 
catabolic reaction does not occur in vitro (Lin and Radin, 1973). Together, these studies established 
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the dogma that psychosine is synthesized via the anabolic pathway. However, the enzyme 
catalyzing this reaction in vivo has never been identified, and the cDNA encoding such an enzyme 
has never been cloned. The existence of such an enzyme remains an open question to this day. 
1.7.4 Demyelination and axonopathy 
Demyelination and axonopathy are major pathogenic mechanisms of Krabbe disease. It is 
well known that psychosine induces demyelination indirectly by causing the death of 
oligodendrocytes and Schwann cells. However, psychosine also directly induces myelin 
breakdown (White et al., 2009). In addition to myelin destruction, defects in protein phosphatase 
signaling (Cantuti-Castelvetri et al., 2012), increases in caspase-3 expression (Smith et al., 2011), 
and abnormal axonal transport (Cantuti-Castelvetri et al., 2013) all contribute to axonal 
dysfunction. 
Axonopathy manifests in Krabbe disease in many ways. Most easily observed are the 
defects in neuromuscular function. Axonopathy contributes to ataxia and other gross motor 
dysfunction in human Krabbe patients as well as in Twi mice. Less obvious are the problems in 
autonomic function that are the result of axonopathy in the autonomic nervous system (ANS). 
Autonomic denervation of lymphoid organs results in thymic atrophy in Twi mice (Galbiati et al., 
2007). 
Although the ANS has not been formally studied in human Krabbe patients, patients do 
exhibit signs of ANS dysfunction, including unstable blood pressure, increased vascular 
permeability, and poor gastrointestinal motility. Krabbe patients are also predisposed to infections, 
a finding that may reflect the abnormal thymic atrophy and T cell production observed in Twi mice. 
Although a very important component of Krabbe disease, peripheral neuropathy is 
nevertheless very difficult to treat. To date, no published experimental therapies effectively and 
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consistently corrects the motor defects observed in Twi mice, even if they significantly increase 
Twi lifespan (Hawkins-Salsbury et al., 2015; Rafi et al., 2015). Future therapies that successfully 
target peripheral neuropathy will likely greatly increase the quality of life for Krabbe patients. 
1.7.5 Neuroinflammation 
Fever of unknown origin is one of the early manifestations of Krabbe disease, suggesting 
the activation of the innate immune response in these patients (Hagberg et al., 1963). The presence 
of phagocytic globoid cells in the brain also points to an inflammatory etiology (Krabbe, 1916). 
Neuroinflammation has further been characterized as a prominent feature of Krabbe disease. 
Human Krabbe disease, as well as all animal Krabbe models, are characterized by profound 
microgliosis and astrocytosis. The dogma in the field has been that the death of oligodendrocytes 
and demyelination directly causes neuroinflammation. While this is certainly true, more recently 
published data suggest that neuroinflammation is an independent pathogenic mechanism, with 
microgliosis beginning as early as two weeks in the mouse (Snook et al., 2014) and perturbations 
in cytokine and chemokine expression occurring as early as postnatal day 2 (Santambrogio et al., 
2012). 
The cause of neuroinflammation in the early stages of Krabbe disease is unclear. Several 
hypotheses have been proposed. Expression of cytokines and cellular markers of inflammation 
increases with psychosine accumulation (Santambrogio et al., 2012), but it is unclear whether 
psychosine accumulates to a significant extent so early on in the disease course. Because it is 
difficult to measure psychosine levels on a single-cell level, it is unclear whether microglia and 
astrocytes accumulate psychosine at all. The only cell types known to accumulate psychosine at a 
pathological level are myelinating cells – oligodendrocytes and Schwann cells (White et al., 2011). 
It has been suggested that GALC-deficient oligodendrocytes may trigger neuroinflammation 
13 
through contact-dependent or independent means (Potter and Petryniak, 2016). Finally, it has been 
hypothesized that GALC-deficient microglia and astrocytes may self-activate, but this hypothesis 
has yet to be experimentally tested. 
Regardless of the etiology of neuroinflammation in Krabbe disease, it has been confirmed 
to be a critical pathogenic mechanism contributing to disease progression. Although the cytokine 
expression profile in the Twi CNS is predominantly pro-inflammatory (Higashi et al., 1992; Ohno 
et al., 1993; LeVine and Brown, 1997; Pedchenko et al., 1999; Pedchenko et al., 2000; Wu et al., 
2001; Formichi et al.,  2007; Pasqui et al., 2007; Luzi et al., 2009; Ripoll et al., 2011), a reduction 
of microglia and circulating monocytes in CSF1-deficient (CSF1-/-) Twi/Osteopetrotic (Op) mice 
impairs myelin phagocytosis and remyelination, exacerbates neurologic symptoms, and shortens 
Twi lifespan (Wiktor-Jedrzejczak et al., 1990; Kondo et al., 2011). Expression of arginase-1 
(Arg1), an anti-inflammatory microglial marker, is increased in Twi CNS but not in Twi/Op CNS  
(Kondo et al., 2011), suggesting that a subpopulation of microglia in the Twi CNS inhibits GLD 
disease progression. Given the global pro-inflammatory environment in the Twi CNS, it is likely 
that microglia with opposing functional roles coexist in the Twi CNS, and that subtle, localized 
changes in cytokine signaling can change microglial function in a particular area. 
 
1.8 Experimental Therapies 
1.8.1 Cross correction 
Cross correction is a well-described phenomenon by which an enzyme-producing cell can 
correct the enzyme deficiency of a neighboring cell (Neufeld and Fratantoni, 1970). This 
mechanism is critically important for the effect of many therapies, including hematopoietic stem 
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cell transplantation and experimental therapies directly targeting the underlying genetic deficiency 
in Krabbe disease. 
In cross correction, nascent lysosomal enzymes of GALC-expressing donor cells are 
glycosylated in the endoplasmic reticulum. They are then transported to the Golgi apparatus, where 
they acquire the mannose-6-phosphate modification. The majority of the modified enzyme is then 
bound to mannose-6-phosphate receptor (M6PR) and targeted to the lysosome. However, a small 
proportion of enzyme is secreted from the cell. These enzymes can be taken up by neighboring 
GALC-/- recipient cells through the ubiquitously expressed M6PR or the mannose receptor, which 
is expressed in cells of the reticuloendothelial system. Once taken up, these enzymes are targeted 
to the recipient cell’s lysosome, where the enzyme dissociates from the receptor (Neufeld and 
Fratantoni, 1970; Kornfeld, 1992). Because M6PR is expressed on every cell type, cross correction 
can, in theory, correct any GALC-/- cell type by providing functional GALC enzyme. In reality, 
however, correction of GALC deficiency is often incomplete. Hematopoietic stem cell 
transplantation, for example, produces ~15% GALC activity normalization in the brain, even with 
complete donor cell engraftment (Hoogerbrugge et al., 1988). 
Despite its limitations, cross correction is an important mechanism by which therapies 
targeting the underlying GALC deficiency must work. Gene therapy, for example, relies heavily 
on cross correction, without which only a very limited population of cells closest to the injection 
sites would be corrected. Because viral tropism further limits the type of cell that can be transduced 
by viral-mediated gene therapy (Hammond et al., 2017), cross correction is especially important 
in that it enables transduced cells overexpressing the deficient enzyme to produce and secrete the 
enzyme so that it can be taken up by neighboring untransduced cells. This significantly increases 
the area of effect. 
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1.8.2 Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation (HSCT) became the standard of care for Krabbe 
disease after it was shown in 1984 that HSCT extended the mean lifespan of Twi mice from 36 
days to 80 days (Yeager et al., 1984). This was the first breakthrough in experimental therapies 
since the Twi model was first published in 1980. Hematopoietic stem cell transplantation was 
thought to provide long term, albeit low GALC activity to the Twi CNS through cross correction 
from donor cells that migrate into the CNS after transplantation (Yeager et al., 1984; 
Hoogerbrugge et al., 1988). However, some recent HSCT studies using a non-lethal conditioning 
regimen with resulting incomplete engraftment have shown no increase in CNS GALC activity 
post-transplant (Reddy et al., 2011). Instead, data from these studies show that HSCT is profoundly 
immunomodulatory. In fact, when administered with gene therapy, HSCT abolishes both disease-
specific microgliosis and gene therapy-specific lymphocytosis in the CNS (Reddy et al., 2011). 
The mechanism underlying the neuroimmunomodulatory effects of HSCT are unknown, but it is 
likely that immunomodulation and cross correction both play important roles in the effectiveness 
of HSCT in treating Krabbe disease. 
1.8.3 Gene therapies 
Monogenic disorders, such as lysosomal storage disorders, are very amenable to gene 
therapy. Thus far, CNS-directed, adeno-associated virus (AAV)-mediated gene therapy has been 
used to restore long-term gene expression and improve clinical outcomes in mouse models of many 
lysosomal storage disorders, including but not limited to mucopolysaccharidosis VII (Skorupa et 
al., 1999), infantile neuronal ceroid lipofuscinosis (Shyng et al., 2017), late infantile neuronal 
ceroid lipofuscinosis (Passini et al., 2006), Niemann Pick A (Passini et al., 2005), and Farber 
disease (Alayoubi et al., 2013). 
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Adeno-associated viruses are non-enveloped, single-stranded DNA viruses that require the 
presence of a helper virus for replication. They are popular as a viral vector for CNS-directed gene 
therapy because of the existence of capsids with CNS-directed viral tropism, their relatively benign 
profile, and their ability to maintain long-term gene expression in hosts (Ojala et al., 2015). Of the 
eleven naturally-occurring AAV capsids, AAV2, 7, 8, 9, and 10 have relatively strong neuronal 
cell tropism. In particular, AAV9 and AAV10 are more recently discovered capsids that have 
improved transduction and broader distribution in the CNS (Cearley and Wolfe, 2006). 
Importantly for CNS diseases that need correction during the neonatal period, such as Krabbe 
disease, AAV9 preferentially targets neonatal neurons and undergoes increased axonal transport 
(Foust et al., 2009; Aschauer et al., 2013). 
The first study of gene therapy in Krabbe disease used the AAV2/1 and AAV2/5 vectors, 
which have the GALC cDNA cloned into the AAV2 backbone and pseudotyped with the AAV1 
and AAV5 capsids, respectively. These studies showed modest improvements in histological and 
clinical measures of disease progression, despite supraphysiologic GALC enzyme activity in the 
brain (Lin et al., 2005; Rafi et al., 2005). One of the limitations of intracranial delivery of viral 
vectors is its limited feasibility in humans due to poor vector spread (Cunningham et al., 2008). 
Intravenous administration of AAV2/rh10-GALC, which has been shown to cross the blood brain 
barrier (Rafi et al., 2012), extended Twi lifespan to a median of about 70 days (Rafi et al., 2015). 
Although Krabbe is a monogenic disorder, correcting the underlying GALC deficiency 
with gene therapy produces very limited improvements in clinicopathological measures. Lifespan 
extension with the latest generation AAV vector alone is less than the extension published in 1984 
with HSCT. These results suggest that there is far more to Krabbe pathogenesis than the underlying 
genetic deficiency, even if it is a monogenic disorder. 
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1.8.4 Substrate reduction therapy 
Because psychosine is generally accepted as the disease-causing agent in Krabbe disease, 
therapies that directly target psychosine synthesis have been proposed as an adjuvant to gene 
therapy. These therapies, termed substrate reduction therapies (SRT), aim to partially reduce the 
synthesis of substrates that accumulate in lysosomal storage disorders. Substrate reduction therapy 
for Krabbe disease decreases the rate of psychosine accumulation in the cell by administration of 
a small molecule that 1) crosses the blood brain barrier and 2) inhibits an enzyme in the pathway 
of psychosine synthesis. 
Currently, the most commonly used SRT in Krabbe disease is L-cycloserine. L-cycloserine 
is a synthetic enantiomer of the naturally-occurring D-cycloserine, a compound isolated from 
bacteria and used pharmaceutically as an antibiotic (Lowther et al., 2010). L-cycloserine inhibits 
serine palmitoyl transferase, an enzyme upstream of ceramide synthesis (Sundaram and Lev, 1984). 
Ceramides, in turn, give rise to psychosine through an unclear pathway. 
L-cycloserine administration improves the clinical course of Krabbe disease in Twi mice, 
increasing their median lifespan to 56.7 days (LeVine et al., 2000) by decreasing CNS psychosine 
accumulation (Hawkins-Salsbury et al., 2015). In dogs, however, L-cycloserine injection had no 
significant effect on lifespan (Duffner et al., 2009). As the dog CNS has a much larger volume 
compared to the mouse CNS, the dog is much more difficult to treat. Since L-cycloserine does not 
treat the underlying genetic defect, it is hardly surprising that L-cycloserine alone has no 
therapeutic effect in dogs. The results from these studies demonstrate that L-cycloserine and SRT 
in general have significant potential in treating Krabbe disease, and may be more effective if 
administered in combination with other therapies targeting the underlying genetic deficiency. 
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Although L-cycloserine is the most common SRT of choice in experimental therapy studies 
for Krabbe disease, it is highly unlikely that it will ever be approved for human use. This is because 
L-cycloserine is not a specific inhibitor of psychosine synthesis. By inhibiting serine palmitoyl 
transferase, L-cycloserine greatly perturbs many lipid pathways in the cell. Adverse effects of such 
a perturbation include the decreased in vivo synthesis of myelin, sulfatides, and gangliosides 
(Sundaram and Lev, 1984), increased CNS GABA levels (Chung et al., 1984), decreased neuronal 
firing (Haas and Wieser, 1980), and decreased expression of alanine and aspartate 
aminotransferases in the liver (Cornell et al., 1984). 
A more specific inhibitor targeting the enzyme directly responsible for catalyzing 
psychosine synthesis would likely have a more favorable safety profile. However, that enzyme 
remains elusive, thwarting all efforts to find a specific inhibitor that targets it. Identifying the in 
vivo pathway of psychosine synthesis would likely spur the discovery of more specific and potent 
inhibitors of psychosine synthesis that could be translated into the clinic. 
1.8.5 Other single therapies 
In addition to HSCT, gene therapy, and SRT, numerous other experimental single therapies 
for Krabbe disease have been published. These include, but are not limited to, enzyme replacement 
therapy, anti-inflammatory therapies, anti-oxidant therapies, oligodendrocyte transplantation, 
neuronal stem cell transplantation, mesenchymal stem cell transplantation, molecular chaperones, 
and GALC enhancers (Mikulka and Sands, 2016). An in-depth discussion of all of these therapies 
is beyond the scope of this dissertation. However, it is important to note that none of the single 
therapies published to date, including the gene therapies, have extended Twi lifespan beyond that 
of the HSCT study published in 1984. 
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The limited efficacy of single therapies in the treatment of Krabbe disease is worth 
discussion. Gene therapy alone, which corrects the underlying genetic defect, is an effective 
therapy for many other simple monogenic disorders such as Leber’s congenital amaurosis type 2 
(Bainbridge et al., 2008), lipoprotein lipase deficiency (Miller, 2012), and hemophilia B (Nathwani 
et al., 2011). Krabbe disease, while monogenic, also has a very complex pathophysiology (see 
discussion in section 1.6). It is likely that targeting only one major pathogenic mechanism as single 
therapies do is insufficient to effectively correct the disease. With that in mind, we turn to 
combination therapies to simultaneously target more than one major pathogenic mechanism in 
Krabbe disease. 
1.8.6 Combination therapies 
The first combination therapy for Krabbe disease showed that HSCT and SRT synergize 
and increase Twi lifespan to 112 days (Biswas and LeVine, 2002). Subsequent studies have shown 
that combination therapies, as a whole, are much more effective than single therapies. Many 
therapies synergize when administered in combination, which results in significant increases in 
Twi lifespan. However, not all therapies synergize (Mikulka and Sands, 2016). With the exception 
of the initial study combining SRT with HSCT, all subsequent therapies that synergize include a 
combination of gene therapy and HSCT (Reddy et al., 2013; Hawkins-Salsbury et al., 2015; Rafi 
et al., 2017). This suggests that together, HSCT and gene therapy treat Krabbe disease through an 
interactive mechanism that requires the presence of both therapies. 
Neuroimmunologic studies have shown that Twi mice have profound microgliosis and 
astrocytosis. Unsurprisingly, perhaps, intracranial and intrathecal injection of AAV2/5 induces 
significant lymphocytic infiltration into the CNS. In Twi mice, AAV2/5 administration also 
worsens microgliosis. These findings may explain why AAV2/5 alone has very limited efficacy in 
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increasing Twi lifespan even though it induces supraphysiologic GALC expression in the Twi 
CNS. Administration of HSCT with gene therapy abolishes both the disease-specific microgliosis, 
the AAV-associated microgliosis, and the AAV-associated lymphocytosis (Reddy et al., 2011).  
A more recent study showed that intravenous (IV) administration of AAV2/rh10-GALC 
and HSCT also greatly extended the lifespan of Twi mice (Rafi et al., 2015). Because AAV2/rh10 
crosses the blood brain barrier, it is likely that IV injection of the virus resulted in significant 
expression of GALC in the CNS and peripheral nervous system (PNS), as well as increasing 
systemic GALC expression. Although no systemic disease has ever been reported in Krabbe, these 
data suggest that targeting systemic GALC expression in addition to the nervous system 
contributes to increased Twi survival. This is not surprising, as GALC is expressed in every cell 
of the body, and is actually most highly expressed in the kidneys. It is likely that GALC has an as 
yet unknown systemic function whose disease manifestations are masked by the rapidly 
progressive CNS disease. 
Taken together, these results show that gene therapy and HSCT work synergistically by 
directly targeting at least two major pathogenic mechanisms of Krabbe disease: the underlying 
genetic defect and neuroinflammation. Addition of L-cycloserine, which directly targets 
psychosine accumulation, to the gene therapy and HSCT produces an even more dramatic increase 
in median Twi lifespan to 298.5 days (Hawkins-Salsbury et al., 2015). The mechanism by which 
L-cycloserine induces synergy is unclear. However, recent studies have shown that L-cycloserine 
increases the expression of M6PR in the Twi CNS (Hu et al., 2016). Because cross correction 
relies on the M6PR to supply enzyme to enzyme-deficient cells, increased expression of M6PR 
would likely increase the number of GALC-deficient cells that are corrected by cross correction. 
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1.9 Toxicity of Adeno-Associated Viruses 
Although AAV vectors have a reputation of low toxicity and low immunogenicity (Naso 
et al., 2017), they have recently been shown to cause severe acute and chronic toxicity in larger 
animal models (Hinderer et al., 2018). Rhesus macaques injected intravenously with an AAV2/9 
vector encoding survival of motor neuron (SMN) at a dose of 2x1014 genome copies per kilogram 
of body weight displayed severe hepatotoxicity. Massive elevation of liver enzymes was observed 
in all injected monkeys, and one macaque expired within four days of injection from acute shock. 
Piglets treated with the same vector at the same dosage by weight demonstrated severe 
neurotoxicity, with all injected animals developing ataxia and paralysis severe enough to require 
euthanasia within 1-3 days. 
Toxicity of adeno-associated viruses is not limited to large animal models. In 2001, the 
first cases of AAV-induced hepatocellular carcinoma (HCC) were reported in a long-term study 
of AAV administration in mice (Donsante et al., 2001). Since this publication, numerous other 
publications have independently shown AAV-induced HCC in mice using different models and 
AAV vectors. At least four factors significantly increase the penetrance of AAV-induced HCC: 1. 
Strong liver tropism 2. Increased promoter strength 3. Increased virus dose, and 4. Neonatal 
delivery of virus (Chandler et al., 2015). 
Although AAV is thought of as a non-integrating virus, integration does occur at a 
significant frequency. In utero intravenous AAV2/9 administration in macaques resulted in up to 
550,000 unique integration sites in liver genomic DNA (Mattar et al., 2017). The Rian locus is an 
integration hotspot in mice, and AAV integration at this site disrupts the expression of multiple 
microRNAs embedded within Rian (Donsante et al., 2007). Disruption of the Rian locus has been 
shown to cause HCC in mice (Wang et al., 2012). 
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The Rian locus lies in an area of the mouse genome that has a corresponding syntenic 
region in the human genome. Fortunately, 32/51 of the reported integration sites lie in a 50-bp 
segment that is unique to the mouse. However, 19/51 integration sites lie in regions that are highly 
conserved with the human genome (Chandler et al., 2016). Whether or not AAV-induced HCC 
will translate to humans is unclear, but currently available data suggest that this is a major area of 
concern. Recurrent clonal insertions of AAV2 have been found in human HCC tumors at a 
frequency of 5% (Nault et al., 2015). A subset of these integrations resulted in overexpression of 
TERT, a telomerase reverse transcriptase that is overexpressed in ~90% of HCC tumors (Jiao et 
al., 2018). 
The ongoing spinal muscular atrophy type I human clinical trial (Mendell et al., 2017) may 
be able to determine whether a causative link between AAV administration and human HCC exists. 
Infants enrolled in this trial received intravenous high-dose AAV2/9 vector encoding SMN. The 
young age of the patients at treatment, the use of the CMV enhancer/chicken β-actin promoter to 
induce high levels of gene expression, the high dose of virus, and the IV route of administration 
make a worrisome combination of factors that may increase the penetrance of AAV-induced HCC. 
Long-term monitoring of these patients may determine whether AAV-induced HCC is a toxicity 
that translates to humans. 
 
1.10 Summary 
Infantile globoid cell leukodystrophy (Krabbe disease) is a rapidly progressive, pediatric 
inborn error of metabolism that is remarkably refractory to treatment. This introduction outlined 
the clinicopathology, the standard of care, the pathophysiology, the animal models, and the 
experimental therapies for Krabbe disease. Although the field of Krabbe research is advancing 
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rapidly, there are many unanswered questions that still need to be addressed. One of the most 
important unanswered questions is the in vivo pathway of psychosine synthesis. Although the in 
vitro pathway was putatively identified in 1960, the enzyme that catalyzes the reaction in vivo has 
not been identified. In Chapter 2 of this dissertation, we present data that irrefutably overturn the 
current dogma of psychosine synthesis by showing that psychosine is synthesized, not anabolically, 
but catabolically through the deacylation of galactosylceramide by acid ceramidase (ACDase). 
These data identify ACDase as a target for SRT that is much more specific for psychosine synthesis 
than the currently-used L-cycloserine. Through this project, we created a GALC-deficient mouse 
model that does not accumulate psychosine, thereby successfully dissociating GALC deficiency 
from psychosine accumulation. The observation that this mouse model does not have any signs of 
Krabbe disease suggests that the longstanding ‘Psychosine Hypothesis’ is correct, and that 
psychosine does indeed cause all the signs and symptoms associated with Krabbe. A better 
understanding of the perturbation of lipid pathways in Krabbe disease may also help to identify 
new biomarkers that would improve the sensitivity of newborn screening. 
Another persistent challenge in the Krabbe field is the lack of an effective therapy. 
Hematopoietic stem cell transplantation, the current standard of care, is less than ideal due to its 
limited efficacy and significant toxicities. In recent years, combination therapies that 
simultaneously target more than one pathogenic mechanism have been shown to be much more 
effective than single therapies. Despite the progress that has been made, much more work remains 
to be done. Specifically, the peripheral neuropathy in the Twi mouse has thus far remained 
stubbornly refractory to treatment. In chapter 3 of this dissertation, we present a combination 
therapy that pushes the median Twi lifespan significantly beyond what has been reported to date. 
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Equally importantly, this combination therapy corrects the motor deficits in Twi mice such that 
many treated mice are still able to perform well on behavioral tests even a few days before death. 
Finally, AAV-induced HCC is a challenge not only for the Krabbe community but also for 
the gene therapy community at large. In the latter part of chapter 3, we present data that show how 
combination of different therapies with AAV-mediated gene therapy can change the penetrance of 
AAV-induced HCC. These data are critically important, because it is likely that a cure for Krabbe 
disease will consist of a multimodal therapy. Only when we are armed with a better understanding 
of the pathogenesis of AAV-induced HCC can we hope to design viral vectors and therapies to 
circumvent this unintended, but potentially fatal adverse effect. 
 
1.11 Figure Legends 
Figure 1.1. Multiple major pathogenic mechanisms contribute to Krabbe disease. Lack of 
GALC activity is the underlying defect, which results in accumulation of the cytotoxic metabolite 
psychosine. Rapid psychosine accumulation in oligodendrocytes and Schwann cells results in 
myelin destruction and demyelination. Generation of oxidative stress further worsens CNS 
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Infantile globoid cell leukodystrophy (Krabbe disease) is a pediatric demyelinating 
lysosomal disorder caused by the deficiency of galactosylceramidase (GALC) activity and 
characterized by the accumulation of the toxic metabolite galactosylsphingosine, commonly 
referred to as psychosine. Over the past six decades, psychosine was believed to be synthesized 
anabolically from galactose and sphingosine. However, neither the enzyme nor the cDNA 
encoding the enzyme responsible for this reaction has been identified. Here, we show that 
psychosine is generated catabolically through the deacylation of galactosylceramide by acid 
ceramidase (ACDase). This reaction effectively dissociates GALC deficiency from psychosine 
accumulation, thus allowing the long-standing ‘Psychosine Hypothesis’ to be directly tested. We 
confirm here that psychosine accumulation is the primary disease-causing mechanism in infantile 
Krabbe disease.  Finally, these data identify ACDase as a potential target for substrate reduction 
therapy.  Pharmacological inhibition of ACDase activity significantly prolongs the lifespan of the 











Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a rapidly progressive and 
invariably fatal demyelinating disorder that was first described in 1916 (Krabbe). Krabbe disease 
is characterized clinically by failure to thrive, limb stiffness, seizures, developmental regression, 
and death by 2-4 years of age (Wenger et al., 2016). The disease is caused by the deficiency of the 
lysosomal enzyme, galactosylceramidase (GALC). Galactosylceramidase cleaves the terminal 
galactose from galactosylated lipids, including the myelin lipid, galactosylceramide, and the 
cytotoxic lipid, galactosylsphingosine (psychosine).  
Psychosine is a cytotoxic metabolite that accumulates most rapidly in oligodendrocytes 
and Schwann cells in vivo (Suzuki and Suzuki, 1983). In 1972, the ‘Psychosine Hypothesis’ was 
proposed, stating that psychosine accumulation is the primary cause of disease manifestations in 
GLD (Miyatake and Suzuki, 1972).  The ‘Psychosine Hypothesis’ has never been formally tested 
due to the inability to dissociate GALC deficiency from psychosine accumulation. 
A seminal study published ~60 years ago concluded that psychosine is synthesized 
anabolically from sphingosine and galactose (Cleland and Kennedy, 1960). A subsequent study 
indirectly supported these data by suggesting that the catabolic deacylation of galactosylceramide 
to psychosine does not occur (Lin and Radin, 1973). Together, these studies established the 
paradigm that psychosine is synthesized via an anabolic pathway (Figure 2.1). However, the 
enzyme catalyzing this reaction in vivo remains elusive. 
The deacylation of glucosylceramide to glucosylsphingosine by acid ceramidase (ACDase) 
is a reaction that closely parallels the hypothetical deacylation of galactosylceramide to 
galactosylsphingosine.  Since neither the enzyme nor the cDNA responsible for psychosine 
29 
synthesis has ever been identified, and because galactose is the stereoisomer of glucose, we 
hypothesized that ACDase may also catalyze the deacylation of galactosylceramide to psychosine.   
The availability of a tractable mouse model of ACDase deficiency (Asah1P361R/P361R, Farber 
disease, FD) (Alayoubi et al., 2013) has enabled us to directly test this hypothesis in vivo. The 
Farber mouse is a model of Farber disease, an inherited pediatric lysosomal storage disorder of 
ceramide accumulation. Patients with Farber disease present in infancy with hoarseness, arthritis, 
and subcutaneous nodules due to laryngeal, joint, and subcutaneous accumulation of ceramide, 
respectively (Levade et al., 1995). Disease progression is characterized by severe 
hepatosplenomegaly, impaired growth, and psychomotor retardation, with death usually occurring 
before two years of age (Haraoka et al., 1997). 
A number of different mutations in the ASAH1 gene causes low acid ceramidase activity 
and Farber disease in human patients. The Farber mouse has a knock-in of a known human ASAH1 
mutation (P361R), which gives rise to a hypomorphic ACDase protein product. This model 
faithfully recapitulates many clinical features of human Farber disease, including severe 
hepatosplenomegaly and subcutaneous ceramide accumulation. More importantly, the Farber 
mouse recapitulates the lipid profile of Farber patients, with massive elevations in all ceramide 
species (Alayoubi et al., 2013). 
We bred the Asah1P361R/P361R mutation onto the Twitcher  (GALC-/-, Twi) mouse, a murine 
model that closely mimics the biochemical, histological and clinical features of Krabbe disease 
(Kobayashi et al., 1980; Duchen et al., 1980; Suzuki and Suzuki, 1983). The drastic phenotypic 
differences between the Twi mice and the Farber mice (Table 1) facilitate the characterization of 
the GALC-/-Asah1P361R/P361R Twitcher/Farber (Twi/FD) double mutant in reference to these mice. 
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We show here that Twi/FD mice have normal levels of psychosine, exhibit none of the 
characteristic Twi phenotypes, and appear nearly identical to Farber mice.  These results 
demonstrate that psychosine production in vivo is mediated by the ACDase-catalyzed catabolic 
deacylation of galactosylceramide. The lack of psychosine accumulation in the context of GALC 
deficiency and the nearly complete absence of the Twi phenotype in the Twi/FD double mutant 
also confirm the long held ‘Psychosine Hypothesis.’ 
Substrate reduction therapy (SRT) that targets psychosine accumulation can partially 
ameliorate the signs of Krabbe disease in the Twi mouse (Levine et al., 2000). However, current 
SRT compounds do not directly inhibit psychosine synthesis; rather they decrease the production 
of galactosylceramide by disrupting upstream synthetic pathways (Sundaram and Lev, 1984; 
Sundaram and Lev, 1985). The data presented here suggest that ACDase could be a novel and 
direct SRT target for the treatment of Krabbe disease.  We show that pharmacologic inhibition of 
ACDase activity by the chemotherapeutic drug Carmofur decreases psychosine accumulation and 
significantly prolongs the lifespan of Twi mice.  Taken together, these data greatly advance our 
understanding of the underlying pathogenic mechanisms leading to GLD and provide the impetus 
to search for safer and more potent ACDase inhibitors as SRT drugs in the treatment of GLD. 
 
2.2 Results 
2.2.1 Acid ceramidase catalyzes the catabolic formation of psychosine 
The deacylation of glucosylceramide to glucosylsphingosine is known to be catalyzed by 
ACDase (Yamaguchi et al., 1994; Ferraz et al., 2016). Since galactose is structurally related to 
glucose, its stereoisomer, we hypothesized that ACDase may also catalyze the production of 
psychosine from galactosylceramide. In a pure in vitro system we showed that recombinant 
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ACDase can remove the fatty acyl chain from galactosylceramide to produce psychosine. The 
addition of carmofur, an inhibitor of ACDase activity (Realini et al., 2013), eliminated psychosine 
formation. (Fig. 2.2A) In order to determine if the same reaction occurs in vivo, we established a 
cell culture system using primary fibroblasts from GALC- and ACDase-deficient mice.  Cells were 
cultured from Twi mice that also harbored a homozygous mutation (Asah1P361R/P361R) in the 
ACDase gene which results in Farber disease (FD) (Alayoubi et al., 2013). Relatively high levels 
of psychosine and ceramide were measured in Twi and FD fibroblasts, respectively. Fibroblasts 
from double mutant (GALC-/-/Asah1P361R/P361R, Twi/FD) mice accumulated high levels of ceramide 
but not psychosine. This is consistent with the data showing that ACDase is responsible for 
psychosine production in vitro. Importantly, reconstitution of ACDase activity following lentiviral 
transduction of Twi/FD fibroblasts resulted in the accumulation of high levels of psychosine (Fig 
2.2B). 
To determine if ACDase catalyzes the formation of psychosine in an intact animal, we 
characterized the Twi/FD double mutant mice. The levels of psychosine in Twi/FD brain, liver, 
spleen, and sciatic nerve were indistinguishable from those in wild type (WT) animals and 
significantly lower than those in Twi mice (Fig. 2.3). Ceramide elevation due to absence of 
ACDase activity was observed in FD and Twi/FD mice, but not in WT or Twi mice. (Fig. 2.4).  
Galactosylceramides were elevated in Twi/FD mice, but not in WT, Twi or FD mice. (Fig. 2.5) 
Together, these data strongly suggest that the deacylation of galactosylceramide by acid 
ceramidase is the primary, if not only, mechanism that leads to psychosine production in vivo. 
2.2.2 Testing and confirmation of the ‘Psychosine Hypothesis’ 
In the Twi/FD mouse, GALC deficiency is effectively dissociated from psychosine 
accumulation. This allowed us to directly test the longstanding ‘Psychosine Hypothesis’, which 
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states that psychosine accumulation is the primary cause of the clinical manifestations of Krabbe 
disease (Miyatake and Suzuki, 1972). The median lifespan of Twi/FD mice (63d) was significantly 
longer than that of Twi mice (42d) and slightly shorter than that of FD mice (74d) (Fig. 2.6). The 
mean maximum body weight of Twi/FD mice was 18.1±1.8 g, which was virtually identical to FD 
mice (18.2±1.9g) and significantly greater than Twi mice (12.2±1.9g). (Fig. 2.7A) Both Twi/FD 
and FD mice had splenomegaly and thymic hypertrophy compared to WT and Twi mice. (Fig. 
2.7B) The hematological abnormalities in Twi/FD mice were similar to those in FD mice with 
larger circulating monocyte (Ly6G-Ly6Chi) and neutrophil (Ly6G+Ly6C+) populations, and 
significantly smaller T lymphocyte (CD3+) populations compared to WT and Twi mice. (Fig. 2.8) 
Tremor is a defining characteristic of the Twi mouse (Duchen et al., 1980). At 36 days, the 
peak tremor frequencies (PTFs) observed in Twi/FD and FD mice (9.0±4.0 Hz and 8.6±2.2 Hz, 
respectively) were not different from WT animals.  In contrast, 36-day-old Twi mice had a PTF of 
17.4±2.2 Hz.  By 63 days, tremor was observed in both Twi/FD (14.6±5.9 Hz) and FD (16.6±3.7 
Hz) mice.  There was no significant difference in PTF between Twi/FD and FD mice at either time 
point. (Fig. 2.9) 
Motor function in Twi/FD mice was assessed by the rotarod (Fig. 2.10A) and wirehang 
(Fig. 2.10B) tests at two time points.  The first, 36 days, represents a time point when Twi mice 
are severely affected but FD mice are virtually asymptomatic; the second, 63 days, is when all the 
Twi mice have died and FD mice have measurable motor deficits. At 36 days, Twi/FD and FD 
mice consistently performed near WT levels on both the rotarod and wirehang tests.  In contrast, 
Twi mice exhibited significant deficits on both tests. At 63d, Twi/FD and FD mice exhibited 
significant motor deficits in both rotarod and wirehang performance, although they still performed 
the wirehang test better than 36-day-old Twi mice. 
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There are various differentiating histological features in the Twi and the FD mice, thus 
facilitating comparative histological analysis of Twi/FD mice (Figure 2.11A). Cerebellar 
inclusions and microgliosis were observed in Twi, FD, and Twi/FD mice, but the inclusion patterns 
were different for the different genotypes. In Twi mice, the macrophages had a multifocal 
distribution without clustering. In addition, the white matter was abnormal with evidence of myelin 
loss. In FD mice, the macrophages were in clusters in the white matter and perivascular spaces. 
Twitcher/FD mice resembled FD mice, with much less storage macrophages scattered throughout 
the white matter compared to Twi mice. In addition, Twi/FD mice showed no evidence of 
demyelination. 
Microglial activation was diffuse in Twi mice, but patchy and concentrated at multiple foci 
in FD mice. Twitcher/FD mice had a mixed phenotype, with very low intensity, diffuse microglial 
activation, as well as focal areas of cerebellar microglial aggregation that were smaller than those 
in FD mice. 
Twitcher spleens had inflammatory infiltrates, while the spleens of FD mice and Twi/FD 
double mutants were vacuolated. However, splenic vacuolization was less severe in Twi/FD mice. 
In Twi mice, destruction of sciatic nerve structure was coupled with significant inflammatory 
infiltrate, decreased myelination, and edema. Sciatic nerves from FD mice and Twi/FD mice, 
however, had significantly less inflammatory infiltrate, with mostly intact axonal structures. 
Quantification of axon density showed normal axon counts in Twi/FD and FD mice, compared to 
a profoundly decreased axon count in Twi mice. (Fig. 2.11B) 
2.2.3 Pharmacological inhibition of acid ceramidase activity 
Because the hypomorphic Asah1P361R/P361R mutation essentially eliminates both psychosine 
accumulation and the Krabbe disease phenotype, we hypothesized that pharmacologic inhibition 
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of ACDase activity could result in clinical benefits in the Twi mouse. Carmofur is a 5-fluorouracil-
releasing chemotherapeutic agent currently used in the treatment of colorectal cancer (Kubota et 
al., 1991; Watanabe et al., 2006). It is also an effective inhibitor of ACDase activity when 
administered in vivo (Realini et al., 2013). Intraperitoneal Carmofur administration significantly 
increased the median lifespan of Twi/FDH mice compared to vehicle-treated Twi/FDH mice (46d 
versus 40d, respectively). (Fig. 2.12A) Interestingly, Carmofur administration did not increase the 
median lifespan of Twi mice that were WT at the ASAH1 locus. (Fig. 2.12B) Importantly, 
Carmofur administration directly decreased psychosine synthesis (Fig. 2.13A), but did not alter 
ceramide levels (Fig. 2.13B) in both Twi and Twi/FDH mice. 
 
2.3 Discussion 
Psychosine plays a critical role in the pathogenesis of Krabbe disease. However, the in vivo 
synthetic pathway of this cytotoxic lipid remains unclear. Although two publications from 1960 
(Cleland and Kennedy, 1960) and 1973 (Lin and Radin, 1973) independently suggested that 
psychosine production occurs by the anabolic dehydration of galactose and ceramide, the enzyme 
that catalyzes this reaction remains a mystery. In this study, we overturn those data and provide 
incontrovertible evidence showing that psychosine is synthesized through the catabolic 
deacylation of galactosylceramide. We further identify the enzyme catalyzing this reaction in vivo 
as ACDase. 
The Twi/FD mouse is an experimental system that dissociates GALC deficiency from 
psychosine accumulation. This allows the testing of the longstanding ‘Psychosine Hypothesis.’ 
Clinicobehavioral and histological analysis of the Twi/FD mouse show that the absence of 
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psychosine accumulation in GALC deficient mice essentially eliminates the Twi phenotype. These 
data confirm the ‘Psychosine Hypothesis,’ at least within the lifespan of the Twi/FD mouse. 
We believe that the slight but significant shortening of lifespan in Twi/FD mice is due to 
the unique accumulation of galactosylceramide, which is a secondary consequence of concurrent 
GALC and ACDase deficiency. These data clarify that both GALC and ACDase participate in the 
in vivo metabolism of galactosylceramide, which explains the confounding observation that Twi 
mice do not accumulate high levels of galactosylceramide (Eto et al., 1970). Given the shortened 
lifespan of Twi/ACD mice, it is likely that supraphysiologic levels of galactosylceramide 
accumulation is toxic, albeit to a lesser extent than psychosine. A detailed description of the 
pathological effects of galactosylceramide accumulation remains to be determined. 
Absence of the classic Twi phenotype in Twi/FD mice suggests that ACDase might be a 
novel target of SRT for Krabbe disease. Experimental SRT for Krabbe disease has been limited to 
L-cycloserine, which indirectly reduces psychosine accumulation by inhibiting serine palmitoyl 
transferase, an enzyme several steps upstream of psychosine synthesis (LeVine et al., 2000). As 
such, it disrupts many other critical sphingolipid pathways (Sundaram and Lev, 1984; Sundaram 
and Lev, 1985). Although L-cycloserine has been instrumental for proof-of-concept experiments 
in the Twi mouse, it is neither efficient nor specific. We hypothesized that decreasing psychosine 
accumulation directly by pharmacological inhibition of ACDase activity could provide clinical 
benefits to the Twi mouse. We performed a proof-of-concept experiment by pharmacologically 
inhibiting ACDase activity in the Twi mouse via Carmofur administration. Although Carmofur 
administration significantly increased the median lifespan of Twi/FDH, this effect was not 
observed in Twi mice. The increased therapeutic efficacy of Carmofur administration in Twi/FDH 
mice suggests that there is a threshold of ACDase activity inhibition that must be reached to 
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produce therapeutic efficacy for Krabbe disease.  Importantly, Carmofur administration did not 
increase ceramide accumulation in the liver even though psychosine levels were decreased by 
nearly 90% compared to vehicle-treated Twi mice. This suggests that there may be an acceptable 
therapeutic window in which ACDase activity can be sufficiently inhibited to decrease psychosine 
accumulation without inducing concurrent ceramide accumulation and Farber disease. 
By its very nature, SRT should slow disease progression, not provide a cure. Therefore, it 
is not surprising that Carmofur partially corrects the Krabbe phenotype, even in Twi/FDH mice.  
We used Carmofur as a commercially-available, proof-of-concept tool to demonstrate the viability 
of pharmacologic ACDase inhibition as an SRT target in Krabbe disease.  Carmofur was not 
designed as a specific inhibitor of ACDase activity. Therefore, it seems likely that a more specific 
and potent inhibitor of ACDase activity could increase therapeutic efficacy in Krabbe disease.  
Substrate reduction therapy has been shown to synergize dramatically with other therapies in the 
treatment of Krabbe disease (Biswas and LeVine, 2002; Hawkins-Salsbury et al., 2015), and the 
incorporation of a potent ACDase inhibitor into a combination therapy regimen would likely 
greatly enhance therapeutic efficacy. 
Finally, it is important to note that in all clinicobehavioral and histological phenotypes, 
Twi mice heterozygous at the ASAH1 locus (GALC-/-/Asah1+/P361R, Twi/FDH) were 
indistinguishable from Twi mice. Conversely, FD mice heterozygous at the GALC locus (GALC+/-
/Asah1P361R/P361R) were indistinguishable from FD mice. These observations suggest that 
heterozygosity at the GALC and the ASAH1 loci do not affect the phenotypes of FD and Twi mice, 
respectively, at least within the ages at which these mice were examined. This is not surprising, as 
most heterozygous carriers of inborn errors of metabolism are phenotypically normal. Those who 
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do develop phenotypic abnormalities generally do so at an advanced age that would be well beyond 
the ages of the mice that were analyzed in this study (Liu et al., 2011; Lee et al., 2015).  
Taken together, the results from this study overturn the nearly 60-year-old dogma stating 
that psychosine is produced through an anabolic pathway. We show instead that psychosine is 
generated catabolically in vitro and in vivo by the deacylation of galactosylceramide by ACDase. 
These data also explain the lack of galactosylceramide accumulation in the human and murine 
Krabbe brains (Eto et al., 1970; Svennerholm et al., 1980). Here, we also confirm the longstanding 
‘Psychosine Hypothesis,’ by demonstrating that GALC-deficient mice do not develop the Krabbe 
phenotypes in the absence of psychosine accumulation. Finally, we identify ACDase as a novel 
SRT target, providing the impetus to discover safer and more effective inhibitors for the treatment 
of Krabbe disease. 
 
2.4 Methods 
2.4.1 Experimental animals 
Animals were housed at Washington University in St. Louis under the supervision of MSS. 
Heterozygous Twi (GALC+/-) mice on a C57BL6 background (Jackson Laboratory, Maine, USA) 
were bred with heterozygous FD (Asah1+/-) mice on a mixed C57BL6 and 129S6 background. 
Genotypes of all experimental mice were determined by PCR, as previously described for the Twi 
mouse (Sakai et al., 1996; Lin et al., 2005) and the FD mouse (Alayoubi et al., 2013). Mice were 
housed under standard conditions with ad libitum access to food and water. Mice were maintained 
on a 12 hr/12 hr light/dark cycle. All animal procedures were approved by the Institutional Animal 
Studies Committee at Washington University School of Medicine and were in accordance with the 
guidelines of the National Institutes of Health. 
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2.4.2 Psychosine production in vitro 
To determine whether ACDase could directly cleave glycosphingolipids, 20uM of C12-
NBD-galactosylceramides (Cayman Chemical) were incubated with 5-10ug of purified acid 
ceramidase in a 30 ul of reaction containing 15 ul of 0.2M citrate phosphate buffer (pH 4.5), 2.25 
ul of 2M NaCl, 1.5ul of 10 mg/ml BSA, and 0.3 ul 10% IGEPAL CA630. The reaction was 
incubated at 37ºC for 18 hours without agitation and then stopped by adding 60 uL methanol. The 
amount of NBD-psychosine released by the action of the enzyme was determined by Acquity 
UPLC (excitation, 435nm; emission, 525nm). 
2.4.3 Lentivirus preparation 
The ASAH1 and α-galactosidase A (AGA) cDNAs were cloned into the lentiviral transfer 
plasmid (pDY) to generate pDY-hASAH1 and pDY-AGA as previously described (Alayoubi et 
al., 2013). Lentiviral stocks were prepared by transient transfection of HEK293T cells using a four-
plasmid system (pCMVR8.91, pMD.G, pAdV and the transfer plasmids) and concentrated by 
centrifugation. Concentrated viral stocks were titered on HEK293T cells and vector copy number 
was determined by quantitative PCR.   
2.4.4 Fibroblast transduction 
Primary subdermal fibroblasts from FD and Twi mice were isolated from newborn animals 
and grown in DMEM supplemented with 10% heat-inactivated FBS, 10 mM HEPES buffer, MEM 
non-essential amino acid solution, 1mM sodium pyruvate, and 1% penicillin/streptomycin under 
5% pCO2 at 37°C. Cells were transduced with lentivirus expressing acid ceramidase (Asah1) or 
aspartylglucosaminidase (control) with a multiplicity of infection of 50. Serum level was dropped 
to 1% 72 hours after transduction. Fibroblasts were maintained at 1% serum level for one week, 
after which they were harvested, pelleted, and stored at -70C for metabolic analyses. 
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2.4.5 Mass spectrometry 
Galactosylsphingosine (psychosine), galactosylceramide, and ceramides were measured in 
brain, liver, sciatic nerve, and spleen, essentially as previously described (Sikora et al., 2017). 
Galactosylsphingosine and galactosylceramide were separated from glucosylsphingosine and 
glucosylceramide by hydrophilic interaction liquid chromatography (HILIC) columns. Ceramides 
were separated on two-dimensional chromatography by HILIC column in the first dimension and 
by reversed phase column in the second dimension. Multiple reaction monitoring (MRM) was used 
to detect galactosylsphingosine, ceramide, and galactosylceramide on an AB SCIEX 4000QTRAP 
tandem mass spectrometer in positive ESI mode. Data processing was conducted with Analyst 
1.5.2 (Applied Biosystems). Data are reported as the peak area ratios of lipids to their internal 
standards. 
2.4.6 Flow cytometry 
Circulating hematopoietic-derived cells from experimental and control animals were 
identified and quantified by fluorescence-activated cell sorting. Red blood cells were lysed, and 
cells were stained with 7AAD (vital stain) and fluorophore-conjugated antibodies after blocking 
with Fc receptor. The following antibodies were used: FITC rat anti-mouse CD3 (T-cells, BD 
Biosciences), APC rat anti-mouse CD11b (monocytes, BD Biosciences), PEcy7 anti-mouse Ly6G 
(monocytes, neutrophils), and eFluor 450 rat anti-mouse Ly6C (monocytes, neutrophils, E-
Biosciences). Data were acquired on the Gallios flow cytometer (Beckman Coulter), and analyzed 
using FlowJo software (Tree Star). 
2.4.7 Histology 
After mice were deeply anesthetized and perfused with phosphate-buffered saline, spleen, 
liver, and one sagittal half of brain were harvested immediately. Tissue samples were 
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cryoprotected in 30% sucrose after being fixed in 4% paraformaldehyde in phosphate buffer for 
24-48 hours at 4C. Tissues were embedded in paraffin for Luxol fast blue and periodic Acid-
Schiff (LFB/PAS) staining. Ten micron sections were mounted on slides for analysis. 
Sciatic nerves were isolated following perfusion with phosphate buffer and fixed in 4% 
paraformaldehyde/2% glutaraldehyde in phosphate buffer. Nerves were incubated in osmium 
tetroxide and then dehydrated in ethanol. After embedding in Araldite 502 (Polysciences), one µm 
sections were prepared using an ultramicrotome and stained with toluidine blue. After mounting 
on slides, images were acquired using the Hitachi CCD KP-MIAN digitizing camera mounted on 
a Leitz Laborlux S microscope. Histomorphometric analysis was carried out using the Leco IA32 
Image Analysis System. 
2.4.8 Behavioral testing 
Behavioral testing consisted of the rotarod and wirehang tests, which were conducted as 
previously reported (Hawkins-Salsbury et al., 2015). Mice were tested once every other week on 
the rotarod and once every week on the wirehang. Performance was measured as the time it took 
the mouse to fall from either apparatus.  Three trials were run for each test, and the average of the 
three trials was reported. For both tests, the maximum tested time was 60 seconds. Each group 
contained at least n=10 animals. 
2.4.9 Actometer testing 
Tremor severity was quantified using a custom-made force-plate actometer as previously 
described (Fowler et al., 2001; Reddy et al., 2011). Maximum tremor frequency was reported for 





One sagittal half of each brain was harvested immediately following perfusion with 
phosphate-buffered saline and fixed in 4% paraformaldehyde for 24-48 hours at 4C and 
cryoprotected in 30% sucrose. Sixteen micron sections were blocked in normal goat serum then 
incubated with primary rabbit anti-mouse GFAP (Immunostar) antibody or rat anti-mouse CD68 
(BioRad), as previously described (Reddy et al., 2011). The sections were then incubated in the 
appropriate horse radish peroxidase-conjugated secondary antibody and developed with a 
commercially available DAB kit (Vector Laboratories). 
2.4.11 Carmofur administration 
Carmofur was obtained from LKT Laboratories. A stock solution of 300 mg/kg solution 
was made in dimethylsulfoxide (DMSO) and stored at -20C. Stock solutions were diluted in 
Solutol (Sigma-Aldrich) and citrate buffer to make the 30 mg/kg working solution immediately 
prior to each injection. Starting at postnatal day 10, all experimental animals received 
intraperitoneal injections of 30 mg/kg Carmofur every 12 hours for the remainder of their lives. 
Control animals received the same dose of DMSO, Solutol citrate solution. 
2.4.12 Statistical analysis 
Statistical significance was calculated using the one-way ANOVA with a Bonferroni correction 
for multiple comparisons, unless otherwise specified. P values are denoted as follows: *p < 0.05; 






Table 2.1 Comparison of the Twitcher vs. Farber murine phenotypes 
 
Table 2.1 Phenotypes that differ significantly between Twi mice and FD mice include average 











2.6 Figure Legends 
Figure 2.1. Potential pathways of psychosine synthesis. Psychosine can be synthesized either 
through the anabolic dehydration of sphingosine and galactose (left), or through the catabolic 
deacylation of galactosylceramide (right). Two studies have directly (Cleland and Kennedy, 1960) 
or indirectly (Lin and Radin, 1973) supported the anabolic pathway. We show here that acid 
ceramidase (ACDase) catalyzes the catabolic production of psychosine in vitro and in vivo. 
Figure 2.2. Acid ceramidase catalyzes the in vitro formation of psychosine.** (A) Recombinant 
ACDase catalyzes the conversion of galactosylceramide (GalCer) to psychosine in vitro. Addition 
of Carmofur, an inhibitor of ACDase activity, prevents psychosine formation. (B) Twitcher (Twi) 
fibroblasts accumulate psychosine compared to WT, FD, and Twi/FD (Twi/FD untransduced) 
fibroblasts. Reconstitution of ACDase activity following lentiviral transduction of Twi/FD 
fibroblasts dramatically increases psychosine accumulation in these cells (Twi/FD LV-ACDase). 
Figure 2.3. Acid ceramidase catalyzes the in vivo formation of psychosine.** Psychosine is 
elevated in brain, sciatic nerve, liver, and spleen in Twi and Twi/FDH mice at 36d and terminal 
age. There is no elevation of psychosine in WT, FD, or Twi/FD mice at either time point. 
Figure 2.4. Ceramides* are elevated in FD and Twi/FD mice at 36d and terminal age** in 
brain, liver, and spleen. In contrast, elevations in ceramide species are not observed in WT, Twi, 
or Twi/FDH mice at either time point. 
Figure 2.5. Accumulation of galactosylceramides* is unique to Twi/FD double mutant 
mice.** Galactosylceramide elevation is observed in brain, liver, and spleen of Twi/FD mice, but 
not in Twi, FD, or WT mice. 
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Figure 2.6. Acid ceramidase deficiency significantly increases lifespan of Twi/FD. Median 
lifespan of Twi/FD mice (63d) is significantly longer than that of Twi mice (42d) and slightly 
shorter than that of FD mice (74d). No WT mice died during the course of this study.  
Figure 2.7. Acid ceramidase deficiency significantly increases body weight, spleen weight, 
and thymus weight in Twi/FD mice. The (A) mean maximum body weight and normalized (B) 
spleen and (C) thymus weights in Twi/FD mice are not significantly different from those in FD 
mice, but are significantly greater than those in Twi mice. 
Figure 2.8. Twitcher/FD and FD mice have fewer increased blood neutrophil and monocytes, 
and fewer blood T cells than WT mice. (A) Blood neutrophil and (B) monocyte populations are 
increased in Twi/FD and FD mice compared to WT mice. (C) The blood T cell population is 
decreased in Twi/FD and FD mice than in WT mice. 
Figure 2.9. Acid ceramidase deficiency attenuates tremor in Twi/FD mice. Peak tremor 
frequencies show that there is prominent tremor in Twi mice but not in WT, Twi/FD or FD mice 
at 5 weeks of age. Tremor is more pronounced in FD and Twi/FD at 9 weeks of age. 
Figure 2.10. Acid ceramidase deficiency normalizes motor function in Twi/FD mice. Twi mice 
have significant motor deficits as measured by the (A) rotarod and the (B) wirehang tests compared 
to WT, FD, and Twi/FD mice at 5 weeks of age. Functional impairment in both behavioral tests 
becomes more severe in FD and Twi/FD mice at 9 weeks of age. 
Figure 2.11. Histology of Twi/FD mice is virtually indistinguishable from that of FD mice. 
(A) Cerebellar inclusions are present in Twi, FD, and Twi/FD mice (black arrows). Twi mice have 
diffuse distribution of macrophages and abnormal myelination in white matter. In FD mice, 
macrophages (PAS-positive globoid cells) cluster in white matter and perivascular spaces. 
Twitcher/FD mice resemble FD mice, and have much fewer storage macrophages scattered 
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throughout the white matter than Twi mice. Furthermore, Twi/FD mice also have less 
demyelination than Twi mice. (B) CD68+ microgliosis (brown staining) is widespread and more 
uniform in Twi mice than in Twi/FD and FD mice. There are focal areas of CD68+ microgliosis in 
FD cerebellum. Twitcher/FD mice also have a hybrid phenotype, with mild and diffuse CD68+ 
microgliosis throughout the cerebellum with small focal areas of microglial activation (purple 
arrows). Microglial aggregates in Twi/FD mice are also smaller than those seen in FD mice. (C) 
Twitcher spleens are characterized by dense inflammatory infiltrate, whereas the spleens of FD 
mice and Twi/FD double mutants are vacuolated (vacuolization outlined by red arrows). Splenic 
vacuolization is less severe in Twi/FD mice. (D) Sciatic nerve structural integrity is severely 
compromised in Twi mice. Significant inflammatory infiltrate, decreased myelination, and edema 
are also observed. In FD and Twi/FD mice, sciatic nerve structure is preserved, although there is 
mild inflammatory infiltrate (green arrows). (E) Axon quantification shows low axon count in Twi 
mice compared to WT, Twi/FD, and FD mice. 
Figure 2.12. Pharmacologic inhibition of acid ceramidase activity increases the lifespan of 
Twi/FDH mice. Carmofur administration significantly increases the median lifespan of (A) 
Twi/FDH mice but not of (B) Twi mice compared to vehicle controls. 
Figure 2.13. Carmofur administration reduces psychosine accumulation but does not 
increase ceramide* levels.** Carmofur administration significantly reduces (A) CNS psychosine 
accumulation in Twi and Twi/FDH mice, but does not alter (B) liver ceramide levels in Twi or 
Twi/FDH mice. 
* Only data for 16:0 species of ceramides and galactosylceramides are shown. The other species 
show similar expression patterns amongst the different genotypes. 
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Increased Efficacy and Toxicty Associated with Combination 










Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a rapidly progressive, 
invariably fatal pediatric disorder caused by the deficiency of the lysosomal enzyme, 
galactosylceramidase (GALC). Absence of GALC activity results in the accumulation of the toxic 
glycolipid, galactosylsphingosine (psychosine). Accumulation of psychosine in the central and 
peripheral nervous systems results in profound demyelination. Although GLD is a monogenic 
disorder, single modality therapies are minimally effective. However, combining central nervous 
system (CNS)-directed, AAV2/5-mediated gene therapy, hematopoietic stem cell transplantation, 
and substrate reduction therapy greatly increased efficacy in the Twitcher (Twi) mouse, a faithful 
model of GLD. In the current study, we replaced AAV2/5 with a newer generation vector, AAV2/9. 
This single change significantly increased the lifespan and dramatically improved, and in some 
cases normalized, the clinical/behavioral deficits compared with the animals treated with the 
combination using the AAV2/5 vector.  Unfortunately, nearly all of the combination-treated Twi 
mice and all combination-treated wild type control mice died from hepatocellular carcinoma. 
Integration site analysis confirms a high rate of AAV sequence integration into the mouse genome.  
These data demonstrate the value of targeting multiple pathogenic mechanisms for complex 








Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a rapidly progressing and 
invariably fatal lysosomal storage disorder caused by the deficiency of galactosylceramidase 
(GALC) activity (Krabbe, 1916; Wenger et al., 2016). This deficiency results in the rapid 
accumulation of psychosine, a toxic glycolipid normally degraded exclusively by GALC. 
Psychosine accumulates rapidly in oligodendrocytes and Schwann cells, leading to a profoundly 
demyelinating phenotype characterized by failure to thrive, limb stiffness, weakness, paralysis, 
blindness, and developmental regression and delay. Symptoms typically appear by 3-6 months of 
age, and death occurs by 2-4 years of age (Wenger et al., 2016). Currently, the only available 
therapy is hematopoietic stem cell transplantation (HSCT), which must be administered prior to 
symptom onset to delay symptom progression (Wright et al., 2017). This treatment is not curative. 
The Twitcher (Twi) mouse is a genetically faithful model of Krabbe disease that closely 
parallels the biochemistry, histology, and clinical progression of the human disease. Twitcher mice 
experience a rapidly progressive disease course, with tremors and ataxia starting at ~21 days, and 
death occurring by ~40 days (Kobayashi et al., 1980; Duchen et al., 1980; Suzuki and Suzuki, 
1983). The Twi mouse has been an indispensable tool for testing new therapies since its publication 
in 1980, but finding an effective therapy has been a challenge. Single modality therapies, including 
gene therapies, HSCT, stem cell therapies, substrate reduction therapies (SRT), and anti-
inflammatories provide only limited clinical benefit, and none are curative. Several groups have 
now shown that combination therapies targeting multiple pathogenic mechanisms are significantly 
more efficacious (Mikulka and Sands, 2016). 
We showed previously that CNS-directed, AAV2/5-mediated gene therapy synergized 
with HSCT to increase the median life span (~110 days) of Twi mice to a greater extent than the 
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sum of the increases from the individual treatments. We subsequently showed that the synergy was 
likely due to AAV-mediated gene therapy supplying a persistent source of the deficient enzyme 
while HSCT provided a significant immunomodulatory effect (Reddy et al., 2011).  Although this 
improvement was a major advance, the increase in lifespan was modest compared to the lifespan 
of a normal laboratory mouse (2-3 years).  Therefore, we added a small molecule SRT drug, L-
cycloserine, to the gene therapy/HSCT regimen in an attempt to further decrease psychosine levels 
by inhibiting its synthesis. The addition of thrice weekly injections of L-cycloserine significantly 
and synergistically increased the median life span (~300 days) and dramatically improved the 
clinical/behavioral (rotarod and wirehang) deficits observed in the Twi mouse (Hawkins-Salsbury 
et al., 2015). 
As we systematically tested these various combination approaches, we kept the second 
generation AAV2/5 vector constant. In the current study, we performed the same triple-treatment 
(3xRx) experiment as described above using the same recombinant AAV genome but packaged 
with an AAV9 capsid. The newer generation AAV vector increased efficacy even further. The 
median lifespan of 3xRx Twi mice was increased to ~400 days and the clinical/behavioral deficits 
were dramatically improved, and in some cases completely normalized for the entire life of the 
animal. Unfortunately, >90% of the 3xRx Twi mice and 100% of the 3xRx normal control mice 
died of hepatocellular carcinoma (HCC) that was observed as early as 8 months of age.  In fact, 
most of the 3xRx Twi mice, even the ones >300 days of age, did not appear to die from Krabbe 
disease. Rather, they succumbed to HCC.   
A high incidence (30-50%) of HCC at ≥1 year of age following intravenous injection of 
AAV vectors in newborn mice has been reported previously by several groups (Chandler et al., 
2016). Although the exact cause of the increased incidence (100%) and decreased latency of HCC 
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in the current study is not known, we hypothesize that AAV integration sites may disrupt 
oncogenes, tumor suppressor genes, and other genes that regulate cell survival and proliferation. 
It is highly likely that the conditioning radiation associated with the HSCT and the L-cycloserine 
also contributed to the increased penetrance of HCC. 
Despite the high penetrance of HCC, these data show that combination therapy is a highly 
effective treatment of murine GLD. Detailed analyses of the tumor and normal-appearing liver 
tissue will undoubtedly provide insights into the potential of these therapies to interact to increase 




Untreated Twi mice had a median lifespan of 41 days (d) (range: 24-46d) (Figure 3.1). 
Adeno-associated virus 2/9-GALC treated Twi mice had a median lifespan of 66.5d (range: 50-
83d). Twitcher mice treated with AAV2/9-GALC and HSCT (2xRx) or AAV2/9-GALC, HSCT, 
and L-cycloserine (3xRx) had median lifespans of 269d (range: 180-673d) and 404d (range: 157-
569d), respectively. Although the median lifespan of the 2xRx-treated Twi mice was 135d less 
than the 3xRx-treated Twi mice, the lifespans were not significantly different. Wild type mice 
treated with the same triple therapy regimen had a median lifespan of 440d (range: 347-507d). All 
untreated WT mice lived to be at least 673d, at which point they were sacrificed to terminate the 
study.  
3.2.2 Body weight 
Untreated Twi mice experience failure to thrive, as indicated by severely impaired weight 
gain, with a mean maximum weight of 7.8±0.5 grams (g). (Figure 3.2) Both 2xRx and 3xRx 
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combination therapy improve weight gain, with body weight plateauing at an average of ~18 g for 
both groups. In contrast, untreated WT mice surpass 30 g on average. WT mice receiving 3xRx 
therapy gain more weight than combination therapy treated Twi mice, but they are significantly 
smaller than untreated WT mice, only reaching an average weight of ~21 g. 
3.2.3 Motor function 
Motor function was assessed by the rotarod and wirehang tests. Untreated Twi mice were 
unable to complete the rotarod or the wirehang test at 4 weeks of age. Untreated WT mice 
performed both rotarod and wirehang for the maximal 60 seconds of testing throughout life. 
Twitcher mice treated with 2xRx therapy were able to perform rotarod near WT levels until 
approximately one month prior to death. Nearly all 3xRx-treated Twi mice performed the rotarod 
test at WT levels throughout life (Figure 3.3A), and were able to maintain a 60s performance until 
they were moribund (Figure 3.3B). 
Twitcher mice receiving 2xRx therapy were able to perform the wirehang test near WT 
levels until 10 weeks of age, after which wirehang performance quickly deteriorated. No 2xRx 
Twi mouse was able to stay on the inverted wire for 60 seconds past 90 days.  At 10 weeks of age, 
Twi mice receiving 3xRx therapy were also able to perform wirehang near WT levels; at twenty 
weeks of age, half of all 3xRx-treated Twi mice remained on the wirehang for 60 seconds, whereas 
the other 3xRx-treated Twi mice were not able to perform the test at all (Figure 3.4A). This 
bimodal distribution was observed at all subsequent testing time points with some 3xRx-treated 
Twi mice able to perform the wirehang test for the full 60 seconds at 455 days of age. 
Wirehang performance at 20 weeks was only weakly predictive of lifespan (Figure 3.4B). 
Specifically, 3xRx-treated Twi mice with lifespan <300 days performed poorly on wirehang at 20 
weeks, and 3xRx-treated Twi mice with lifespan >435 days performed well on wirehang at 20 
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weeks. Between 300 and 435 days, however, wirehang performance was poorly predictive of 
lifespan, with some Twi mice performing for the full 60 seconds of testing and some Twi mice 
falling off the wirehang as soon as it was inverted. 
3.2.4 Biochemical analyses 
The brains of Twi mice had virtually undetectable levels of GALC activity when compared 
to that of their WT littermates (Figure 3.5). All mice treated with AAV2/9-GALC gene therapy, 
either as a single therapy, 2xRx or 3xRx, had at least WT levels of GALC activity. Some mice 
treated with AAV2/9-GALC gene therapy had up to 2.5 times WT levels of GALC activity. GALC 
activity remained high throughout the lifetime of the treated mice.  There was no significant 
difference in brain GALC activity between animals receiving AAV2/9-GALC single therapy, 
2xRx therapy, or 3xRx therapy. 
For both brains (Figure 3.6A) and sciatic nerves (Figure 3.6B), psychosine levels were 
significantly decreased in AAV2/9-GALC only and combination therapy treated mice, compared 
to untreated Twi mice. There was no significant difference in brain or sciatic nerve psychosine 
levels between mice treated with AAV2/9-GALC single therapy, 2xRx therapy, or 3xRx therapy.  
Psychosine levels remained low throughout the lifetime of single and combination therapy treated 
mice. However, there remained a slight elevation in psychosine compared to WT levels at nearly 
every time point in treated whole brain lysate and sciatic nerves. 
3.2.5 Donor cell engraftment 
Twitcher mice treated with 2xRx or 3xRx combination therapy had mean GFP+ donor 
engraftment levels of 52.9±19.9% and 46.9±20.2%, respectively. WT mice treated with 3xRx 
therapy had a mean engraftment level of 44.6±18.0%. There is no significant difference in 
engraftment amongst these three groups. (Figure 3.7) 
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3.2.6 Peripheral neuropathy 
Untreated Twi mice had fewer axons, significant edema and macrophage infiltration in the 
sciatic nerve compared to WT mice. (Figure 3.8A) In Twi mice receiving 3xRx therapy, there were 
fewer infiltrating monocytes/macrophages and less edema than untreated Twi mice at 36 days, but 
these abnormalities were observed at 160 days. Neither gene therapy alone nor 2xRx therapy 
corrected the axonal pathology at any time. Quantification of axon density revealed lower axon 
density in Twi mice, and incomplete normalization of axon density in Twi mice receiving 3xRx 
therapy. (Figure 3.8B) 
3.2.7 Immunohistochemistry 
Compared to WT mice, Twi mice had profound neuroinflammation, characterized by 
increased CD68+ microgliosis (Figure 3.9) and GFAP+ astrocytosis (Figure 3.10) on 
immunohistochemistry. Neuroinflammation was much more intense in the hind brain (cerebellum 
and brain stem) than in the cortex. Combination therapy attenuated microgliosis and astrocytosis 
in 36 day old Twi mice. As Twi mice aged, both CD68 and GFAP staining increased steadily. 
However, terminal 3xRx-treated Twi mice had significantly less microgliosis than terminal 2xRx-
treated Twi mice, especially in the cortex. Triple therapy significantly increased astrocytosis in 
WT mice. 
3.2.8 Cytokine levels 
Whole-brain homogenates showed significant elevations in eotaxin, G-CSF, KC, MCP-1, 
MIP-1α, MIP-1β, and RANTES in untreated 36 day old Twi brains compared to their WT 
littermates. (Figure 3.11) Gene therapy alone failed to normalize cytokine overexpression in 
terminal mice, but both 2xRx and 3xRx therapy normalized cytokine overexpression at earlier and 
later timepoints in the brain. 
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3.2.9 Hepatocellular carcinoma 
Intravenous administration of AAV gene therapy during the neonatal period has been 
shown to cause hepatocellular carcinoma (HCC) in mice (Chander et al., 2016). We observed large 
HCC tumors (Figure 3.12) in 14/16 Twi mice treated with 3xRx therapy, 2/10 Twi mice treated 
with 2xRx therapy, and 19/19 WT mice treated with 3xRx therapy (Figure 3.13). Because the 
penetrance of HCC was much lower in 2xRx-treated Twi mice than in 3xRx-treated Twi mice, we 
hypothesized that L-cycloserine may play an important role in HCC carcinogenesis. L-cycloserine 
significantly altered the ceramide synthetic pathway by increasing the levels of ceramide 16:0 
species, which promote cell proliferation (Senkal et al., 2010; Senkal et al., 2011). (Figure 3.14A) 
L-cycloserine also decreases the levels of pro-apoptotic ceramide 18:0 species (Koybasi et al., 
2004; Karahatay et al., 2007; Senkal et al., 2007) (Figure 3.14B) in liver. 
Although AAV is primarily considered to be a non-integrating virus (Naso et al., 2017), 
integration site analysis revealed frequent AAV integration into the murine genome, with >6,000 
unique integration sites in Twi mice and >23,000 unique sites in WT mice. There was an increased 
number of total unique integration sites in HCC tissue compared to normal liver tissue. (Table 3.1) 
This finding was present in nearly every chromosome in both WT (Figure 3.15A) and Twi (Figure 
3.15B) mice. However, on chromosome 11, the number of unique integration sites found in normal 
tissue was nearly five times the number found in HCC tissue. Integrations occurred more 
frequently in introns, genes, and intergenic regions (Figure 3.16). 
 
3.3 Discussion 
Globoid cell leukodystrophy is a severe, rapidly progressing pediatric lysosomal disorder 
for which there is currently no cure. Although GLD is a monogenic disorder and numerous 
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experimental therapies have been tested since the murine model was first reported in 1980, GLD 
has remained largely refractory to treatment. This is likely due to the presence of multiple 
secondary pathogenic mechanisms that must be simultaneously targeted in addition to the primary 
genetic defect to produce significant therapeutic efficacy. In this study, we treated Twi mice with 
a triple therapy regimen that simultaneously targets three major mechanisms. Central nervous 
system-directed, AAV2/9-mediated gene therapy provides long-term GALC expression. 
Hematopoietic stem cell transplantation ameliorates neuroinflammation (Reddy et al., 2011). L-
cycloserine is a small molecule drug that slows psychosine accumulation by targeting serine 
palmitoyl transferase, an enzyme that catalyzes a step early in the ceramide synthesis pathway 
(Sundaram and Lev, 1984). This combination therapy resulted in the greatest reported median 
lifespan of Twi mice to date. This increase in lifespan is a significant improvement over other 
recently published combination therapy studies (Hawkins-Salsbury et al., 2013; Rafi et al., 2015; 
Ricca et al., 2015; Karumuthil-Melethil et al., 2016). However, the data presented in those studies 
are consistent with our observation that combination therapies are much more effective than single 
therapies in treating Krabbe disease. 
These results have important implications for therapy studies that are currently moving to 
larger mammalian models of Krabbe disease. Preliminary data in dogs have shown that AAV-
mediated gene therapy increases the lifespan of Krabbe dogs (Bradbury et al., 2018). Moreover, 
nonhuman primate studies have shown that gene therapy effectively induces gene transfer in 
neurons, astrocytes, and oligodendrocytes close to the injection site (Meneghini et al., 2016). It 
will be very interesting to see whether the synergy observed in murine combination therapy will 
translate to other larger mammalian models. 
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Another aspect of GLD that remains largely refractory to treatment is motor dysfunction, 
which is quantified by the rotarod and wirehang behavioral assays. Rotarod measures coordination, 
whereas wirehang is a surrogate measure for peripheral neuropathy, limb strength, and 
coordination. While previous therapy studies have reported some improvements in both rotarod 
and wirehang performance (Hawkins-Salsbury et al., 2015; Rafi et al., 2015), improvements have 
been limited, with mice falling off both apparatuses as GLD progressed.  In the current study, 
3xRx-treated Twi mice were able to stay on the rotarod for their entire lives.  The wirehang test is 
a more challenging exercise since untreated Twi mice cannot perform the task for 60 seconds at 
any point in their lives, and treated mice fail this test prior to failing on the rotarod. Interestingly, 
half of the Twi mice receiving 3xRx therapy were able to perform wirehang for the maximal time 
tested (60 seconds) throughout life. In contrast, Twi mice treated with 2xRx therapy were able to 
perform the wirehang test for 60 seconds at 10 weeks of age, but experienced a rapid decline in 
performance after 10 weeks. These data suggest that L-cycloserine plays an important role in 
correcting peripheral neuropathy in Twi mice. This is supported by the greater pathological 
improvements observed in the sciatic nerves of 3xRx-treated mice compared to 2xRx-treated mice. 
Despite the significant improvement in lifespan and motor function, Twi mice treated with 
3xRx therapy retain some signs and symptoms of GLD, including a milder but persistent tremor 
and hind limb clasping. One potential explanation for continued disease progression is the uneven 
distribution of AAV2/9-mediated gene expression in the CNS and PNS, which has previously been 
described in other studies (Cearley and Wolfe, 2006). Although GALC levels were at least 
physiologic and psychosine accumulation was significantly reduced in whole brain lysates of 
3xRx-treated Twi mice, it is possible that uneven distribution of GALC expression, specifically 
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the lack of GALC expression in certain uncorrected areas of the CNS/PNS, translates to continued, 
albeit slower disease progression. 
Another potential cause of GLD progression is the slow but progressive worsening of 
neuroinflammation in the treated Twi CNS. Untreated Twi mice have profound microgliosis and 
astrocytosis (Reddy et al., 2011; Snook et al., 2014), as well as significantly increased expression 
of pro-inflammatory cytokines as early as postnatal day 2 (Santambrogio et al., 2012). Both 2xRx 
therapy and 3xRx therapy normalized cytokine levels. However, the increased 
immunohistochemical staining for CD68 and GFAP as combination treated Twi mice age suggests 
the existence of localized unattenuated inflammation in the CNS that may be masked in whole 
brain assays of cytokine expression. It is likely that the uncontrolled microglial and astrocytic 
activation eventually contribute to Twi disease progression. 
It is interesting to note that there is less microglial activation in terminal 3xRx-treated Twi 
mice than in terminal 2xRx-treated Twi mice. Given this finding, and the observation that 3xRx-
treated Twi mice have better motor function than 2xRx-treated Twi mice, it is surprising that there 
is no significant difference in lifespan between these two groups. In fact, the longest lived Twi 
mouse was a 2xRx-treated animal that lived to be 673 days. In contrast, the longest lived 3xRx-
treated Twi mouse died at 569 days. Since nearly all the 3xRx-treated Twi mice had advanced 
HCC at necropsy and many of them could still perform the rotarod and wirehang tests just prior to 
death, it is almost certain that the 3xRx mice did not die of Krabbe disease; rather, they died of 
HCC.  The true efficacy of the triple therapy is likely masked by the presence of HCC. 
This is further supported by the fact that Twi mice treated with AAV2/5-GALC, HSCT, 
and L-cycloserine triple therapy (median lifespan: 454 d) lived much longer than Twi mice treated 
with AAV2/5-GALC and HSCT double therapy (median lifespan: 120 d). We would expect to see 
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a similarly dramatic increase in lifespan for the AAV2/9-GALC 3xRx treated Twi mice compared 
to AAV2/9-GALC 2xRx treated Twi mice, as a result of the addition of L-cycloserine to the 2xRx 
treatment regimen. This is especially true given that the AAV2/9 2xRx treated Twi mice (269 d) 
lived more than twice as long as the AAV2/5 2xRx treated Twi mice (120 d) (Hawkins-Salsbury 
et al., 2015). It is not clear how long the 3xRx Twi mice would have lived if it were not for the 
HCC. 
Systemic AAV administration has now been associated with acute toxicity in primate and 
porcine models (Hinderer et al., 2018), as well as chronic toxicity (HCC) in mouse models 
(Donsante et al., 2001; Chandler et al., 2015). The HCC observed in mice is caused by AAV 
integration into the mouse genome and subsequent dysregulation of genes and non-coding RNAs 
downstream from the viral-encoded promoter/enhancer. One of the hot spots for integration in the 
mouse is the Rian locus (Donsante et al., 2007; Wang et al., 2012), which disrupts the expression 
of regulatory microRNA 341 and a host of genes implicated in HCC development (Wang et al., 
2012), including Rtl1 (Chandler et al., 2016). Although it is not known if the link between AAV 
administration and HCC translates to humans, it is especially concerning that recurrent clonal 
insertions of AAV2 have been found in human HCC tumors (Nault et al., 2015), and that a subset 
of these integrations resulted in the dysregulation of genes known to be overexpressed in human 
HCC tumors (Jiao et al., 2018). 
Interestingly, integration site analysis of the mice in this study revealed only a single mouse 
which had a clear integration site in the Rian locus. This suggests that the mechanism by which 
combination therapies induce AAV-associated HCC may be very different from the mechanism 
by which AAV therapy alone induces HCC. 
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Prior studies show that the HCC phenotype has a relatively long latency (12-18mo) and the 
frequency is greatest (30-75%) when the animals are injected during the neonatal period. Finally, 
tumorigenesis is independent of serotype but there appears to be a direct correlation between the 
strength of the promoter/enhancer element and the incidence of HCC (Chandler et al., 2016). 
Although HCC has been described in mice injected with AAV vectors as young adults (Bell et al., 
2006), the incidence is considerably less (10-15%). 
In the current study, approximately 90% of the 3xRx-treated Twi and 100% of the 3xRx-
treated WT mice had large HCC tumors at death.  The fact that these mice developed HCC is 
noteworthy in itself since these animals received CNS-directed gene therapy. All of the previous 
studies reporting a high incidence of HCC were performed in newborn animals that received 
intravenous injections of virus. Another significant difference is that the HCC was observed as 
early as 8-10 months of age in the current study. Combination therapy decreased the latency of 
tumorigenesis and increased the incidence of HCC, compared to previously reported latency and 
incidence of AAV-induced HCC (Chandler et al., 2015). 
The shorter latency and higher penetrance of HCC in 3xRx-treated mice may be explained 
by Knudson’s hypothesis, which states that cancer results from the accumulation of multiple ‘hits’ 
to the genome (Knudson, 1971). Prior data strongly suggest that AAV integration represents one 
‘hit’ and may even be sufficient to cause HCC in the mouse.  Pre-conditioning γ-irradiation could 
represent an additional ‘hit’ since ionizing irradiation is known to cause small genomic insertions 
and deletions (Adewoye et al., 2015). Although there were only a few animals in the 2xRx group 
that developed HCC, it could be that they simply did not live long enough for the HCC to develop, 
as most cases of AAV-induced HCC are observed after one year post-exposure. 
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L-cycloserine might also represent another ‘hit’ that could potentiate carcinogenesis. L-
cycloserine, while not a known mutagen, significantly perturbs ceramide metabolism and alters 
the levels of ceramides that influence cell survival. Twi mice treated with L-cycloserine had higher 
levels of ceramide 16:0 species, which have been shown to promote cell proliferation and survival 
(Senkal et al., 2010; Senkal et al., 2011). L-cycloserine also lowers levels of the pro-apoptotic 
ceramide 18:0 species (Koybasi et al., 2004; Karahatay et al., 2007; Senkal et al., 2007). Disrupting 
the balance between cell survival and apoptotic factors is likely to facilitate tumorigenesis. 
Analysis of AAV integration sites revealed significantly more unique integration events in 
HCC tissue compared to normal liver tissue. Since normal and HCC tissue samples were collected 
from each mouse, these results suggest, perhaps unsurprisingly, that increased integration 
frequency is associated with tumorigenesis. 
Breakdown of integration site analysis by chromosome shows that the pattern of increased 
integration sites in HCC tissue compared to normal tissue holds for nearly every chromosome. The 
most striking exception is chromosome 11, which appears to have nearly five times as many unique 
integration sites in normal liver tissue than in HCC tissue. This may indicate the presence of an 
integration hot spot on this chromosome that is not associated with tumorigenesis. 
Functional analysis of AAV integration sites reveals that there are more integration sites 
localizing to genes in HCC tissue than in noncancerous tissue. While the exact implication of this 
finding is not yet clear, it is reasonable to speculate that disruption of genes is more likely to result 
in functional consequences than disruption of noncoding regions. Whether the gene disruptions 
identified in this study cluster around oncogenes or other genes impacting cell survival remains to 
be determined. 
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The 3xRx combination therapy proposed in this study is a very effective therapy for Krabbe 
disease. Not only does it increase lifespan, it also improves motor function in Twi mice. However, 
administration of this therapy is not without its risks. Adeno-associated virus-induced HCC in 
mice is a very real and serious phenomenon that needs further study. There is a clear need to 
understand the role of AAV in the development of HCC, determine how other therapies interact 
with AAV to change the penetrance and latency of tumorigenesis, explore alternative methods of 
bone marrow conditioning, and discover more specific inhibitors of psychosine synthesis. Only 
when we have successfully eliminated AAV-induced HCC in the mouse can we devise 
experiments designed to find a cure for this invariably fatal disease. 
 
3.4 Methods 
3.4.1 Experimental animals 
Animals were housed at Washington University in St. Louis under the supervision of MSS. 
Heterozygous Twitcher (GALC+/-) mice on a C57BL/6J background (Jackson Laboratory, Maine, 
USA) were bred and maintained. Genotypes of all experimental mice were determined by PCR, as 
previously described (Sakai et al., 1996; Lin et al., 2005). Mice were housed under standard 
conditions, on a 12 hr/12 hr light/dark cycle with ad libitum access to food and water. 
Hematopoietic stem cell donors were syngenic GALC+/+ mice that expressed GFP under the CAG 
promoter (Okabe et al., 1997). All animal procedures were approved by the Institutional Animal 
Studies Committee at Washington University School of Medicine and were in accordance with the 




3.4.2 Virus production 
The AAV2/9 vector consists of the CMV enhancer, the chicken β-actin promoter, followed 
by the mouse GALC cDNA and the rabbit β-globin polyadenylation signal, as previously described 
(Lin et al., 2005). The AAV2/9-GALC vector was produced by the Virus Vector Core Facility at 
the Gene Therapy Center of the University of North Carolina. Virus was diluted in sterile Lactated 
Ringer’s solution to a final concentration of 1012 viral particles per mL and stored at -80°C. 
3.4.3 Treatment regimen 
Intracranial and intrathecal injections of AAV2/9-GALC were administered on postnatal 
day 0, as previously described (Hawkins-Salsbury et al., 2015). Briefly, mice received one 15 uL 
intrathecal injection of virus at a concentration of 1012 viral particles per mL. In addition, six 2 uL 
intracranial injections were administered at the same concentration, targeting bilateral hemispheres, 
thalami, and cerebelli. 
Hematopoietic stem cell transplantation was performed on postnatal day 1, as previously 
described (Hawkins-Salsbury et al., 2015). Briefly, mice were conditioned with 400 rads total body 
irradiation from a 137Cs source, then injected with 106 nucleated donor bone marrow cells from a 
GALC+/+GFP+/- donor. Quantification of bone marrow chimerism was determined by flow 
cytometry for donor-derived GFP expression in recipient bone marrow. 
L-cycloserine was administered subcutaneously as previously described (Hawkins-
Salsbury et al., 2015). Briefly, L-cyloserine was reconstituted fresh in phosphate buffered saline 
before each injection. Mice received 25 mg/kg L-cycloserine three times a week until postnatal 




3.4.4 Galactosylceramidase activity assay 
Experimental mice were deeply anesthetized and perfused with phosphate buffered saline. 
One brain hemisphere was flash frozen and homogenized in ddH2O.  Measurement of GALC 
activity was performed using a radiolabeled 3H-galactosylceramide substrate and reported as the 
nanomoles of substrate cleaved per hour per milligram of total protein, as previously described 
(Hawkins-Salsbury et al., 2015). 
3.4.5 Mass spectrometry 
Galactosylsphingosine (psychosine) and ceramides were measured in brain, liver, and 
sciatic nerve, essentially as previously described (Sikora et al., 2017). Galactosylsphingosine was 
separated from glucosylsphingosine and glucosylceramide by hydrophilic interaction liquid 
chromatography (HILIC) columns. Ceramides were separated on two-dimensional 
chromatography by HILIC column in the first dimension and by reversed phase column in the 
second dimension. Multiple reaction monitoring (MRM) was used to detect galactosylsphingosine 
and ceramides on an AB SCIEX 4000QTRAP tandem mass spectrometer in positive ESI mode. 
Data processing was conducted with Analyst 1.5.2 (Applied Biosystems). Data are reported as the 
peak area ratios of lipids to their internal standards. 
3.4.6 Behavioral testing 
Behavioral testing consisted of the rotarod and wirehang tests, which were conducted as 
previously reported (Hawkins-Salsbury et al., 2015). Mice were tested once every other week on 
the rotarod and once every week on the wirehang. Performance was measured as the time it took 
for the mouse to fall from either apparatus.  Three trials were run and the average of the three trials 
was reported for each time point. For both tests, the maximum tested time was 60 seconds. Each 
group contained at least n=10 animals. 
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3.4.7 Immunohistochemistry 
Mice were deeply anesthetized and perfused with phosphate-buffered saline. One sagittal 
half of each brain was harvested immediately following perfusion. Tissues were fixed in 4% 
paraformaldehyde for 24-48 hours at 4C and cryoprotected in 30% sucrose. Sixteen micron 
sections were blocked in normal goat serum then incubated with primary rabbit anti-mouse GFAP 
(Immunostar) antibody or rat anti-mouse CD68 (BioRad), as previously described (Reddy et al., 
2011). The sections were then incubated in the appropriate horse radish peroxidase-conjugated 
secondary antibody and developed with a commercially available DAB kit (Vector Laboratories). 
3.4.8 Histology 
Sciatic nerves were isolated and immediately fixed in 4% paraformaldehyde/2% 
glutaraldehyde. Incubation of nerves in osmium tetroxide was quickly followed by serial 
dehydration in ethanol and embedding in Araldite 502 (Polysciences). One µm cross sections were 
prepared using an ultramicrotome. These sections were then stained with 1% toluidine blue and 
mounted on slides. Image acquisition was completed with a Hitachi CCD KP-MIAN digitizing 
camera mounted on a Leitz Laborlux S microscope. The Leco IA32 Image Analysis System was 
used for histomorphometric analysis. 
3.4.9 Cytokine measurement 
Brains were perfused with phosphate-buffered saline, followed by immediate flash 
freezing and homogenization in a solution containing protease inhibitor cocktail. Cytokine levels 
were quantified using the Bio-plex Pro Mouse Cytokine 23-plex Assay (Bio-Rad) with the help of 




3.4.10 Statistical analysis 
Statistical significance was calculated using a one-way ANOVA with post-hoc Bonferroni 
correction for multiple comparisons, unless otherwise specified. P values are denoted as follows: 























Table 3.1 Unique integration sites in normal vs. HCC tissue  
 
Table 3.1. Unique AAV integration sites in HCC tumors vastly outnumber those in normal 
liver tissue. In tissue isolated from 3xRx-treated Twi mice, there are 2,077 unique integration sites 
in normal-appearing liver tissue (3xRx Normal) and 4,334 unique integration sites in HCC tissue 
(3xRx HCC). In 3xRx-treated WT mice, there are 8,260 unique integration sites in normal-











3.6 Figure Legends 
Figure 3.1. Triple combination therapy increases lifespan and improves clinicobehavioral 
performance in Twi mice. Kaplan-Meier curves showing increased lifespan in Twi mice treated 
with AAV2/9-GALC+HSCT+L-cycloserine triple therapy (3xRx) (n=18), AAV2/9-
GALC+HSCT double therapy (2xRx) (n=13); and AAV2/9-GALC single therapy (n=22) 
compared to untreated Twi mice (n=10). Wild type mice treated with 3xRx therapy (n=19) had a 
significantly shorter lifespan than untreated WT mice (n=11). Asterisks indicate mice that had 
large hepatocellular carcinoma tumors at death. 
Figure 3.2. Combination therapies improve weight gain in Twi mice but cause weight loss in 
WT mice. Untreated Twi mice (Twi Untreated) have profoundly impaired weight gain compared 
to WT mice (WT Untreated). Double (Twi 2xRx) and triple (Twi 3xRx) combination therapy 
partially improve weight gain in Twi mice, but WT mice receiving 3xRx therapy (WT 3xRx) have 
mildly impaired weight gain compared to untreated WT mice. 
Figure 3.3. Triple combination therapy normalizes rotarod performance in Twi mice. (A) 
Rotarod testing shows consistently normal rotarod performance in 3xRx-treated Twi mice (Twi 
3xRx) throughout life. Double combination therapy (Twi 2xRx) also significantly improves 
rotarod performance, but Twi mice eventually start falling off the rotarod as disease progresses. In 
contrast, untreated Twi (Untreated Twi) mice rarely perform the rotarod test for the full 60 seconds 
and are dead by 5-6 weeks of age. (B) Premoribund rotarod performance was assessed one to seven 
days prior to death. Twitcher mice treated with 3xRx therapy perform just as well as untreated WT 
(data not shown) and 3xRx-treated WT mice (WT 3xRx) up until death. In contrast, untreated Twi 
mice and Twi mice treated with 2xRx therapy can no longer perform rotarod when premoribund. 
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The average age at testing for mice in each experimental group is indicated in its corresponding 
column. 
Figure 3.4. (A) Twitcher mice receiving double therapy (Twi 2xRx) and triple therapy (Twi 3xRx) 
have near-normalized wirehang performance at 10 weeks of age. Impairment in wirehang 
performance begins after 10 weeks of age for 2xRx-treated Twi mice. Some 3xRx-treated Twi 
mice can perform wirehang up to 65 weeks, while others are unable to perform wirehang starting 
at 20 weeks. In contrast, all untreated Twi mice have died by 10 weeks, and are unable to do the 
wirehang test at any point in life. Untreated WT mice are able to perform wirehang consistently 
throughout life (data not shown). (B) In 3xRx-treated Twi mice, wirehang performance at 20 
weeks is weakly predictive of lifespan (r2 = 0.2589). Twitcher mice living to <300 days perform 
poorly on wirehang at 20 weeks, whereas Twi mice living >435 days perform well on wirehang at 
20 weeks. Between 300 and 435 days, 20-week wirehang behavior is poorly predictive of lifespan. 
Figure 3.5. AAV2/9-GALC single therapy and combination therapies significantly increase 
GALC activity in the brain. GALC activity is deficient in untreated Twi brains (Twi Untr). 
Compared to untreated WT mice (WT Untr), Twi mice treated with AAV2/9-GALC gene therapy 
alone (Twi AAV2/9), 2xRx therapy (Twi 2xRx), and 3xRx therapy (Twi 3xRx) have at least 
physiologic levels of GALC activity in the brain.  
Figure 3.6. AAV2/9-GALC single therapy and combination therapies decrease psychosine 
accumulation in brain and sciatic nerve.* Psychosine levels in (A) brain and (B) sciatic nerves 
are much higher in untreated Twi mice (Twi Untr) compared to untreated WT mice (WT Untr) 
and Twi mice treated with AAV2/9-GALC gene therapy alone (Twi AAV2/9), 2xRx therapy (Twi 
2xRx), or 3xRx therapy (Twi 3xRx). All therapies significantly decrease psychosine accumulation 
in brain and sciatic nerves throughout the lives of Twi mice. 
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Figure 3.7. Wild type and Twi mice receiving HSCT engraft at the same levels. There is no 
significant difference in GFP+ bone marrow engraftment in Twi mice receiving 2xRx (Twi 2xRx) 
or 3xRx (Twi 3xRx) therapies. WT mice receiving 3xRx therapy (WT 3xRx) also have the same 
level of engraftment as Twi mice receiving 2xRx or 3xRx therapy. 
Figure 3.8. Combination therapy significantly delays progression of sciatic nerve pathology. 
(A) Untreated Twi mice (36d Twi) have severe sciatic nerve pathology with decreased myelination, 
profound axonal degeneration, and macrophage infiltration. Triple combination therapy (36d 3xRx) 
is more effective than 2xRx therapy (36d 2xRx) at preservation of structural integrity in 36 day 
old mice. Severe sciatic nerve pathology is observed at terminal age in 3xRx-treated Twi mice 
(Term 3xRx) compared to WT mice (Term WT). (B) Untreated Twi mice (Twi Untr) have 
significantly decreased axon density in the sciatic nerve. Triple therapy (Twi 3xRx) significantly 
corrects this abnormality at 36d, but decreased axon density remains uncorrected in 160d and 
terminal 3xRx-treated Twi mice. 
Figure 3.9. Triple therapy attenuates microgliosis early in the GLD disease course. Anti-
CD68 immunohistochemistry shows profound microglial activation (brown staining) in untreated 
Twi (36d Twi) brain stem (BS), cerebellum (CB), and cortex (Cort). Double combination therapy 
(36d 2xRx Twi) decreases microgliosis at 36d, but is unable to prevent eventual disease 
progression and development of severe microglial activation by terminal age (Term 2xRx Twi). 
Microgliosis in terminal 3xRx-treated Twi mice (Term 3xRx Twi) is less severe than that in 2xRx-
treated Twi mice (Term 2xRx Twi), especially in the cortex. Aging WT brains (Term WT) develop 
mild microglial activation throughout the brain. 
Figure 3.10. Combination therapies attenuate astroglial activation in the Twi brain. Anti-
GFAP immunohistochemistry shows profound astroglial activation (brown staining) in untreated 
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Twi (36d Twi) brain stem (BS), cerebellum (CB), and cortex (Cort). Astrocyte activation is 
decreased in 2xRx- (36d 2xRx Twi) and 3xRx-treated (36d 3xRx Twi) 36-day-old Twi mice. 
Terminal combination therapy-treated (Term 2xRx Twi and Term 3xRx Twi) Twi mice have 
profound astrogliosis, especially in the cerebellum. Astrocyte activation is slightly decreased in 
terminal Twi mice treated with 3xRx therapy compared to Twi mice treated with 2xRx therapy. 
Astrocyte activation increases as WT mice age (Term WT), and 3xRx therapy causes some 
astroglial activation in WT mice (Term 3xRx WT). 
Figure 3.11. Combination therapies normalize cytokine expression in the Twi brain. (A) G-
CSF, (B) KC, (C) MCP-1, (D) MIP-1α, (E) MIP-1β, and (F) Eotaxin are significantly elevated in 
untreated Twi (Twi Untr) CNS. Gene therapy alone (Twi AAV2/9) attenuates expression of these 
cytokines at 36d. However, by the time these mice are terminal, cytokine expression in Twi mice 
receiving AAV2/9 alone no longer differs from that of untreated Twi mice. Both 2xRx (Twi 2xRx) 
and 3xRx (Twi 3xRx) therapies effect long-term normalization of cytokine expression. 
Figure 3.12. Large HCC tumors are found during necropsy of 3xRx-treated Twi mice. 
Representative images of gross normal liver (top panel) and HCC tumor (bottom panel) isolated 
from a terminal 3xRx-treated mouse. 
Figure 3.13. Triple therapy dramatically increases the penetrance of AAV-induced HCC. 
Penetrance of HCC is significantly increased in 3xRx-treated Twi (Twi 3xRx) and WT (WT 3xRx) 
mice compared to 2xRx-treated Twi mice (Twi 2xRx). 
Figure 3.14. L-Cycloserine administration alters ceramide expression.* Differential 
expression of (A) ceramides 16:0 species (which increase cell proliferation and survival) and (B) 
ceramides 18:0 species (which are pro-apoptotic) in normal-appearing (Twi 3xRx Normal) vs. 
HCC (Twi 3xRx HCC) liver tissue. 
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Figure 3.15. Unique integration sites in tumor tissue outnumber those in normal-appearing 
liver tissue on nearly every chromosome. Chromosomes 4, 11, 17, are relative hotspots for AAV 
integration in (A) WT mice. Chromosomes 4, 8, and 17 are relative hotspots for AAV integration 
in (B) Twi mice. In WT mice, chromosome 11 is an outlier in that there are ~5 times as many 
unique integration sites in normal-appearing liver tissue compared to HCC tissue. In all other 
tissues, unique integration sites in HCC tissue outnumber those in normal-appearing liver tissue. 
Figure 3.16. Unique integration sites occur in all structurally distinct parts of the genome. 
Mapping of unique integration sites in (A) WT and (B) Twi liver tissue shows unique integration 
sites in all parts of the genome. In WT and Twi mice, genes, introns, and intergenic regions are the 
most frequent sites of integration. 












3.7 Figures      
 
Figure 3.1 Survival  
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Figure 3.4 Wirehang performance 
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Krabbe disease is a pediatric lysosomal storage disorder characterized by deficiency of 
galactosylceramidase (GALC) activity and psychosine accumulation, which results in severe 
neurologic impairment and demyelination (Wenger et al., 2016). Psychosine is a toxic metabolite 
that accumulates most quickly in oligodendrocytes and Schwann cells, but also accumulates in 
other cells of the body. 
Early infantile Krabbe disease is characterized by disease onset before 1 year old, with 
rapid progression and death usually occurring before 2 years of age. Affected patients present with 
irritability and gastrointestinal dysmotility, upper and lower motor neuron signs, autonomic 
dysfunction, immune defects, and sensory loss (Krabbe, 1916; Hagberg, 1963). Patients 
experience profound demyelination in the central and peripheral nervous systems (CNS and PNS), 
accompanied by neuronal cell death, axonal damage, and severe neuroinflammation. Globoid cells 
accumulate in the CNS, as microglia and/or macrophages fuse in an attempt to clean up myelin 
debris (Collier and Greenfield, 1924; Blackwood and Cumings, 1954; Austin and Lehfeldt, 1965). 
Although this disease was described in 1916 (Krabbe), and the first animal model was 
reported in 1980, there is no cure. Standard of care consists of hematopoietic stem cell 
transplantation (HSCT), which prolongs life and delays symptom progression if administered 
before symptoms onset (Wright et al., 2017). Otherwise, patients are managed symptomatically 
with the goal of keeping them as comfortable as possible (Escolar et al., 2016). There are no 
clinical trials for Krabbe disease. 
The first animal model for Krabbe disease (the Twitcher mouse, Twi) was published in 
1980 (Kobayashi et al.; Duchen et al.). This murine model is an excellent model for infantile 
Krabbe disease because it parallels the genetics, biochemistry, histology, and clinical progression 
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of the human disease. Because they breed quickly and are relatively cheap to maintain, Twi mice 
have been the primary animal model in the field of Krabbe research. 
4.1.1 Outstanding questions in the field 
There are many outstanding questions in the Krabbe field. Of primary importance is the 
biochemistry of in vivo psychosine synthesis. Although psychosine has been hypothesized to be 
the primary disease-causing agent in Krabbe disease, it is unclear how it is synthesized. A study 
published in 1960 showed that the anabolic pathway of psychosine synthesis occurs in vitro, and 
another independent study published in 1973 concluded that the catabolic pathway does not occur 
(Cleland and Kennedy, 1960; Lin and Radin, 1973). Together, these two publications established 
the dogma that psychosine synthesis occurs through the anabolic dehydration of galactose and 
sphingosine. However, neither the enzyme nor the cDNA encoding the enzyme has ever been 
identified, turning this supposed dogma into a mystery that has yet to be solved. 
Another puzzling biochemical observation in the field of Krabbe research is the lack of 
galactosylceramide accumulation in patients and animal models with Krabbe disease (Eto et al., 
1970; Svennerholm et al., 1980). Galactosylceramidase, the enzyme defective in this disease, is so 
named because galactosylceramide is its substrate. However, galactosylceramide does not 
accumulate in the absence of the enzyme responsible for degrading it. It has been assumed that 
another pathway of galactosylceramide degradation that is independent of GALC must exist. 
However, such a pathway has never been identified, and the enzyme catalyzing this putative 
reaction remains elusive. 
A better understanding of psychosine synthesis may provide a way to test the 40-year-old 
‘Psychosine Hypothesis,’ which states that psychosine accumulation, rather than GALC deficiency, 
is the primary cause of symptomatology and disease progression in Krabbe disease (Miyatake and 
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Suzuki, 1972). Although this hypothesis is generally accepted in the field, there has so far been no 
way to test it because of the inability to experimentally dissociate GALC deficiency from 
psychosine accumulation. Once the enzyme that catalyzes psychosine synthesis is identified, 
inhibition of this enzyme in a GALC-deficient background may finally provide the experimental 
setup to test this >45-year-old hypothesis. 
A better understanding of the biochemistry of Krabbe disease is also critical for 
development of substrate reduction therapy (SRT). Substrate reduction therapy uses small 
molecule drugs that cross the blood brain barrier to inhibit psychosine synthesis and slow the 
buildup of this toxic compound. Currently, there are no SRTs in use in the clinic, and L-cycloserine 
is the experimental SRT therapy of choice (LeVine et al., 2000). Unfortunately, L-cycloserine is 
very unlikely to be approved for patient use, because it inhibits serine palmitoyl transferase, an 
enzyme that is many steps upstream of psychosine synthesis (Sundaram and Lev, 1984; Sundaram 
and Lev, 1985). As such, it perturbs many lipid metabolism pathways, and is known to cause 
unintended effects, including decreased synthesis of myelin (Sundaram and Lev, 1984) and 
changes in neuronal firing (Haas et al., 1980). 
Discovery of a more specific inhibitor of psychosine synthesis is impeded by the lack of 
understanding of how psychosine is produced. Identification of the enzyme directly responsible 
for catalyzing psychosine formation would likely facilitate the development of a drug that 
specifically targets this enzyme. Until this enzyme is identified, progress in SRT development for 
Krabbe disease will be restricted. 
Krabbe disease has been remarkably refractory to treatment. The current standard of care 
is not curative, and derives from a murine experimental therapy study that was published in 1984 
(Yeager et al.). No single therapy since then has been able to effect a greater increase in lifespan. 
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In more recent years, we have shown that combination therapies have much greater efficacy than 
single therapies, likely because they simultaneously target more than one major pathogenic 
mechanism of Krabbe disease. In addition, some experimental therapies synergize to dramatically 
increase Twi lifespan (Reddy et al., 2013; Hawkins-Salsbury et al., 2015; Rafi et al., 2017). Despite 
significant progress made in lifespan extension, the motor deficits associated with Krabbe disease 
have been largely refractory to treatment for all experimental therapies published so far. Peripheral 
neuropathy and neuromuscular dysfunction significantly impair quality of life for patients with 
Krabbe disease. Future therapies that successfully treat this facet of the disease would significantly 
improve the quality of life for Krabbe patients. 
Although much progress has been made in gene therapy for this monogenic disease, data 
have come to light that show a causative relationship between adeno-associated virus (AAV) 
administration and hepatocellular carcinoma (HCC) in mice (Wang et al., 2012; Chandler et al., 
2015). This is a very concerning finding, as HCC is an incurable cancer that results inevitably in 
patient death. While it is unclear whether the AAV-HCC relationship observed in mice will 
translate to humans, research in this area is urgently needed. In addition to determining the 
mechanism by which AAV causes hepatocarcinogenesis, research is also needed to determine how 
other therapies could change the penetrance of AAV-induced HCC. This is especially true, because 
clinical trials for Krabbe will likely consist of an experimental therapy that is added to the current 
standard of care. If gene therapy is to be studied in a clinical trial, we need to understand how 
HSCT could affect the penetrance of AAV-induced HCC. 
4.1.2 Questions answered in chapter two 
In chapter two, we showed that acid ceramidase (ACDase) catalyzes the in vitro and in vivo 
catabolic deacylation of galactosylceramide to psychosine. We cultured fibroblasts that were 
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deficient in GALC and ACDase activity, and showed that these fibroblasts did not accumulate any 
psychosine compared to Twi fibroblasts. We then restored ACDase activity through lentiviral 
transduction, and showed that restoring ACDase activity resulted in significant psychosine 
accumulation. These data completely overturn the 60-year-old dogma of anabolic psychosine 
synthesis and identify ACDase as the direct catalyzer of catabolic psychosine synthesis. 
We next bred and characterized the GALC-/-Asah1-/- (Twitcher/Farber, Twi/FD) double 
mutant mouse. We showed that Twi/FD mice do not accumulate psychosine. As such, it is an 
experimental system that completely dissociates GALC deficiency from psychosine accumulation. 
We showed that the absence of psychosine accumulation in the context of the GALC-/- mutation 
completely abolishes all signs and symptoms of Krabbe disease. These results confirm the >45-
year-old hypothesis, at least within the lifespan of the Twi/FD mouse, and show that psychosine 
accumulation, not GALC deficiency, causes the Krabbe phenotype. 
The lack of the Krabbe phenotype in the double mutant is accompanied by a dramatic 
elevation of galactosylceramide that is unique to the Twi/FD mouse. Because Twi/FD mice don’t 
live as long as FD mice but resemble FD mice phenotypically in all other aspects, we hypothesized 
that galactosylceramide accumulation is the likely cause of the slightly shortened lifespan. These 
data show that ACDase provides an alternate pathway for galactosylceramide metabolism in the 
absence of GALC activity. This explains why galactosylceramide elevation is not observed in Twi 
mice. Only when GALC activity and ACDase activity are both deficient does galactosylceramide 
accumulate. 
Finally, we identified ACDase as a novel SRT target for Krabbe disease, and showed that 
pharmacologic inhibition of ACDase activity extends Twi lifespan. These data will catalyze the 
search for more potent and specific inhibitors of ACDase. Unlike L-cycloserine, which is a 
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nonspecific inhibitor of psychosine synthesis, small molecule drugs targeting ACDase will be 
much more specific for psychosine synthesis, and would thus be more likely to have safety profiles 
acceptable for clinical use. 
4.1.3 Questions answered in chapter three 
 In chapter three, we characterized the efficacy of a combination therapy consisting of 
AAV2/9-mediated gene therapy, HSCT, and L-cycloserine. We previously tested the same triple 
therapy, but with a second-generation AAV2/5 vector, and showed that the combination therapy 
produced a dramatic increase in lifespan (Hawkins-Salsbury et al., 2015). In this study, we show 
that using a newer third generation AAV2/9 vector not only produces a greater improvement in 
lifespan, but also successfully treats the motor deficits associated with Krabbe disease. Every Twi 
mouse treated with the triple therapy (3xRx) combination was able to perform the rotarod function 
test from weaning until death. Although the wirehang test is significantly harder than the rotarod, 
half the 3xRx-treated Twi mice were able to consistently perform the wirehang test from weaning 
until death. Such normalization of motor function has never before been reported for the Twi 
mouse. 
These results suggest that AAV2/9, which has been shown to have increased axonal 
transport (Foust et al., 2009; Aschauer et al., 2013), increased CNS penetrance (Cearley and Wolfe, 
2006), and increased transduction (Cearley and Wolfe, 2006), effectively targets the peripheral 
neuropathy and neuromuscular deficits in Krabbe disease. Because Twi mice treated with 
AAV2/9-mediated gene therapy and HSCT double therapy do not experience correction of motor 
deficits, L-cycloserine must interact with gene therapy and/or HSCT to restore motor function and 
prevent peripheral neuropathy. 
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Although AAV2/9 is a more effective vector than AAV2/5 in many respects, AAV2/9 is 
also associated with an increased penetrance of AAV-induced HCC. We showed that the 
administration of other therapies in conjunction with AAV2/9-mediated gene therapy could 
significantly decrease the latency and increase the penetrance of AAV-induced HCC. In particular, 
L-cycloserine seems to dramatically increase the frequency of AAV-induced HCC in Twi and WT 
mice to nearly 100%. Whether this is a function of L-cycloserine alone, or whether L-cyloserine 
must interact with the other administered therapies to produce this effect is unknown. Metabolomic 
comparison of HCC vs. normal-appearing liver tissue indicates that L-cycloserine alters the levels 
of different ceramide species, which may alter cell survival. If this is indeed how L-cycloserine 
effects its carcinogenic properties, it is possible that the use of a more specific inhibitor of 
psychosine synthesis that doesn’t perturb other pathways of lipid metabolism may prevent the 
unintended, increased penetrance of AAV-induced HCC. 
We performed integration site analysis to determine if AAV integration sites differed 
between HCC liver tissue and normal liver tissue from the same animal. Integration analysis shows 
that the number of unique AAV integration sites is much higher in HCC liver tissue than in normal 
liver tissue. Integrations occur most frequently in genes, especially in HCC tissue. This is not 
surprising, as we would expect disruptions to genes to produce a negative functional effect. It is 
unclear if the proteins expressed by genes that are most perturbed by AAV integration cluster in 
any gene ontology group. If, for example, oncogenes are commonly affected, that could explain 




4.2 Future Directions 
4.2.1 Small molecule inhibitors of acid ceramidase 
 Current SRT for Krabbe disease relies on inhibiting psychosine synthesis by inhibition of 
serine palmitoyl transferase, an upstream enzyme in lipid metabolism (Sundaram and Lev, 1984). 
Identification of ACDase as the enzyme directly responsible for psychosine synthesis provides the 
impetus to perform large-scale drug screens to discover potent inhibitors of ACDase to more 
specifically inhibit psychosine synthesis. 
Carmofur is a chemotherapeutic that has also been identified as an inhibitor of ACDase 
activity (Realini et al., 2013). In chapter 2, we showed that Carmofur extended the lifespan of Twi 
mice heterozygous at the ACDase-encoding locus, but not of Twi mice WT at that locus. The 
natural follow-up study is to increase the dose of Carmofur. However, increasing the dose of 
Carmofur may produce unintended results, as over-inhibition of ACDase may produce a Farber 
phenotype, similar to the phenotype of Twi/FD mice. Therefore, we hypothesize that combining 
Carmofur with another small molecule inhibitor that acts at a different point in the psychosine 
synthesis pathway may result in significant lifespan extension in Twi mice. Since psychosine is 
produced from galactosylceramide and ceramide galactosyltransferase (CGT) catalyzes the 
formation of galactosylceramide, simultaneous SRT inhibition of ACDase and CGT may produce 
a significant therapeutic effect without causing unwanted adverse effects. Combination of such an 
SRT with other therapies, such as gene therapy and HSCT, would likely further increase Twi 
lifespan beyond that reported in chapter 3 of this dissertation. 
4.2.2 Liver-detargeted gene therapy 
The triple combination therapy consisting of AAV2/9-GALC gene therapy, HSCT, and L-
cycloserine significantly extended Twi lifespan beyond any reported in previously published 
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studies. We made the argument in chapter 3 that the Twi mice treated with this triple combination 
therapy died from HCC instead of Krabbe disease. Thus, HCC represents a brick wall that is 
impeding further therapeutic progress. 
One way to scale this brick wall is to use a liver de-targeted AAV vector to minimize AAV 
transduction in the liver. Liver-detargeted AAV9 vectors have been published (Pulicheria et al., 
2011), and a liver-detargeted AAV 2/8 vector has been successfully used in vivo to enhance gene 
delivery to muscle in a hamster model of muscular dystrophy (Rotundo et al., 2013). Systemic 
delivery of AAV-GALC has been shown to significantly increase Twi survival (Rafi et al., 2017). 
Thus, intravenous administration of a liver de-targeted AAV vector that penetrates the blood brain 
barrier may not only decrease the penetrance of AAV-induced HCC, but also enhance survival in 
Krabbe disease by increasing gene delivery to both the CNS, PNS, and systemic tissues. 
4.2.3 Systematic study of AAV-induced hepatocellular carcinoma 
We observed a decreased latency and a dramatically increased incidence of AAV-induced 
HCC in mice treated with AAV2/9-GALC, HSCT, and L-cycloserine triple combination therapy. 
Penetrance was 100%, an especially startling percentage, because C57BL6 mice are known to be 
relatively cancer resistant (Nakamura et al., 1992). In contrast, we did not observe an increase in 
AAV-induced HCC penetrance in AAV2/9-GALC and HSCT double therapy (2xRx) treated Twi 
mice. This may be because most of the 2xRx-treated mice died before the end of the latency period 
of approximately one year. In order to determine the effect of HSCT on AAV-induced HCC, WT 
mice need to be treated with the double therapy regimen and assessed for development of liver 
tumors. 
Although AAV integration into the mouse genome causes HCC, the mechanism by which 
carcinogenesis occurs is unclear. One hypothesis is that integration disrupts the expression of cell 
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survival genes, which in turn renders the cell resistant to apoptosis. We isolated tumor and normal 
liver tissue from each mouse that developed HCC in the combination therapy study to identify 
integration sites that contribute to HCC carcinogenesis. Although the data obtained from this 
analysis are important, the combination therapy study was not originally designed to compare HCC 
and normal tissue, and thus has many limitations. To test the hypothesis proposed above, a larger 
study designed specifically for this purpose must be set up to facilitate genomic analysis of AAV 
integration sites in conjunction with gene expression profiling. 
4.2.4 In utero hematopoietic stem cell transplantation 
Although HSCT for Krabbe disease is generally performed in infancy or early childhood, 
abnormal levels of psychosine elevation are detectable in the affected fetus as early as the second 
trimester of pregnancy (Ida et al., 1994). The existence of in utero HSCT (IUHCT) raises the 
possibility of prenatal therapeutic intervention (Vrecenak and Flake, 2013). Although IUHCT has 
not yet achieved clinical potential, the technique is well-documented in mice (Nijaga et al., 2011). 
Proof-of-concept experiments should be performed to determine if IUHCT could improve clinical 
outcome in Twi mice. If IUHCT is indeed effective, combining IUHCT with other therapies could 
produce greater therapeutic benefits than current postnatal transplantation techniques. 
 
4.3 Concluding Remarks 
 Krabbe disease is a monogenic disease with a complex pathophysiology. Finding an 
effective therapy to target its many facets has been exceedingly difficult. The data presented in 
this dissertation significantly advance the field in numerous ways. We answered one of the most 
basic questions of Krabbe pathophysiology by determining the pathway of psychosine synthesis 
as the catabolic deacylation of galactosylceramide. By identifying the enzyme catalyzing this 
112 
reaction as acid ceramidase, we also identified a novel and specific therapeutic target that will 
catalyze the development of more potent SRTs. Finally, we set up an experimental system that 
dissociates GALC deficiency from psychosine accumulation, which allowed us to test and confirm 
the long-standing ‘Psychosine Hypothesis.’ 
 In terms of therapy, we developed a new combination therapy that significantly prolonged 
Twi lifespan. Equally importantly, this therapy corrected the motor deficits associated with Krabbe 
disease. Finally, we showed that HSCT and L-cycloserine administration decreased the latency of 
AAV-induced HCC from 1 year to 8 months. Combination therapy also increased the penetrance 
of AAV-induced HCC to nearly 100%. Although additional research is needed to determine the 
mechanism responsible for these changes, these data emphasize that AAV-induced HCC is a 
serious complication of AAV-mediated gene therapy that needs to be addressed. We hypothesize 
that the use of a liver-detargeted AAV vector will significantly decrease the penetrance of AAV-
induced HCC. 
 We have systematically tested combination therapies by changing only one treatment at a 
time. However, all three therapies in the current combination therapy regimen could be improved. 
Gene therapy could be improved by using a liver-detargeted gene delivery system; hematopoietic 
stem cell transplantation may be more efficacious if administered in utero; a combination SRT 
targeting ACDase and CGT would likely be more potent and benign than the currently-used L-
cycloserine. (Figure 4.1) We hypothesize that a combination therapy with all three of those 





4.4 Figure Legends 
Figure 4.1. Potential improvements to the current triple combination therapy. Gene delivery 
using a liver-detargeted AAV9 vector may significantly reduce the frequency of AAV-induced 
HCC. In utero hematopoietic stem cell transplantation may provide prenatal correction of 
psychosine elevation and other abnormalities in Krabbe disease. Combination substrate reduction 
therapy that targets ACDase and CGT may result in significant retardation of psychosine 
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